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G protein-coupled receptors (GPCRs) are dynamic membrane proteins that bind 
extracellular molecules to transduce biological signals. Although GPCRs represent the 
largest class of targets for therapeutic agents, ligand-binding sites have been precisely 
defined for only a small percentage of the receptors in the human genome. A general cell-
based photocrosslinking approach was developed to investigate the binding interfaces 
necessary for the formation of GPCR signaling complexes. Amber codon suppression 
was extended to facilitate the incorporation of photoactivatable unnatural amino acids, p-
benzoyl-L-phenylalanine and p-azido-L-phenylalanine, into engineered GPCRs 
expressed in mammalian cells in culture. Proof-of-concept studies were carried out in 
chemokine receptors C-X-C chemokine receptor 4 (CXCR4) and C-C chemokine 
receptor 5 (CCR5), which are known HIV-1 co-receptors required for HIV-1 cellular 
entry in CD4+ cells. A cyclic peptide CXCR4-specific inhibitor, T140, photocrosslinked 
primarily to a specific site on CXCR4 and the result was reconciled with existing 
structural biology data. A small molecule drug, maraviroc, photocrosslinked to multiple 
sites on CCR5 and the results were extended to develop a computer homology model of 
the CCR5-maraviroc complex.  In summary, the application of a novel targeted cell-
based photocrosslinking strategy provided detailed information about receptor-ligand 
complexes in two chemokine receptors.  The general approach described here using 
genetically-encoded photoreactive molecules to study the binding interactions between 
GPCRs and ligands represents a significant advance in the application of 
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CHAPTER 1: Introduction 
 
1.1. Physiological Role of GPCRs in Biology and Disease.  
Adapted in part with permission from (Grunbeck, A., et al. (2012) ACS Chem. Biol. 7, 
967-972). Copyright (2012) American Chemical Society. 
 
G protein-coupled receptors (GPCRs), the largest group of cell-surface receptors, 
are ubiquitously expressed throughout the human body. These transmembrane proteins 
have a characteristic heptahelical structure and couple to a cytoplasmic heterotrimeric G 
protein, which is comprised of an α, β, and γ subunit (Figure 1-1). GPCR-dependent  
	  
Figure 1-1. Schematic of a prototypical G protein-coupled receptor structure. The seven 
transmembrane spanning helices are labeled with H. Some GPCRs have also been 
reported to have an eighth helix, but this is not pictured here. Every receptor has three 
loop regions on the extracellular surface of the receptor, which are designated here with 
an e. Each receptor also has three loops on the cytoplasmic surface of the receptor, which 
are labeled here with an i.  
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signaling pathways regulate many critical biological processes by responding to 
environmental signals. A few examples of GPCR modulators are hormones, odorants, 
neurotransmitters, light, and cytokines. In the prototypical GPCR signaling paradigm, 
binding of an extracellular ligand to a receptor results in G protein activation by 
catalyzing GDP-GTP exchange 1. The G protein subunits then dissociate and stimulate 
activity of other cellular components 2. Research over the last several decades has found 
that the GPCR signaling network is much more complex and diverse than the classical 
paradigm suggests 3. Therefore further investigations into the structure and function of 
GPCR signaling complexes are necessary to understand the molecular mechanisms of 
specific signaling events, especially those involved in disease.  
The onset and progression of many diseases involves the mutation and 
dysfunction of GPCRs. The infamous role of GPCRs in disease has resulted in this class 
of proteins being the largest group of molecular targets for drug research 4. To design and 
develop drugs to target a specific receptor requires knowledge of the receptor’s structure 
and function. The β-adrenergic receptors, for instance, are important pharmaceutical 
targets due to their role in regulating the circulatory system and the wealth of information 
known about their structure and dynamics. The Nobel Prize in Chemistry was awarded in 
2012 to Robert Lefkowitz and Brian Kobilka for their research on the β-adrenergic 
receptor system and the contributions they made towards the understanding of GPCR 
function in general. Rhodopsin, a light activated receptor, is another well-characterized 
GPCR.  One of the initial discoveries in the rhodopsin field, which had a significant 
impact on the GPCR field, was the finding that light induces conformational changes in 
rhodopsin, which in turn transduce a signal in the photoreceptor cell 5. Following this 
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discovery, it was quickly appreciated that the functional activity of rhodopsin was 
directly dependent on its conformational state. Structure-function studies on rhodopsin 
and the β-adrenergic receptors have provided some insight into how GPCRs are 
activated, but have raised many unanswered questions about the activation process of 
other GPCRs.  
There are over one thousand proteins expressed in humans that are characterized 
to have a heptahelical structure. Only a handful of these have been investigated to the 
extent of rhodopsin and the β-adrenergic receptors, and a large percentage remains to be 
orphan receptors 6. Two inherent qualities of GPCRs that make them exceptionally 
difficult to investigate are their low expression levels and requirement of an amphipathic 
membrane for function. Researchers spend years optimizing conditions to circumvent 
these hurdles. One probable solution is to develop novel techniques to investigate GPCRs 
in their native environment and on a small scale. In the Sakmar Lab, we are interested in 
creating a set of tools to probe the structure and function of low expressing GPCRs in 
their native membrane environment.  
 
1.1.1. Chemokine Receptors and HIV Entry  
 
For this thesis project, we focused our studies on the two Family A or rhodopsin-
like GPCRs, C-C chemokine receptor 5 (CCR5) and C-X-C chemokine receptor 4. CCR5 
is a member of the C-C chemokine receptor family and is activated by the chemotactic 
cytokines, also referred to as chemokines, which include macrophage inflammatory 
protein-1α (MIP)-1α, MIP-1β, and regulated-and-normal-T cell-expressed and secreted 
(RANTES) 7. The native chemokine ligand for CXCR4 is stromal cell derived factor-1α 
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(SDF-1α) or CXCL12 8,9. Both CXCR4 and CCR5 couple to the inhibitory heterotrimeric 
G protein, Gi, in the cytoplasm. Ligand binding to the receptor catalyzes G protein 
activation as in the classical paradigm. Desensitization of the receptor-signaling pathways 
is initiated through phosphorylation of the C-terminus of the receptor. The cytoplasmic 
protein β-arrestin then binds to the phosphorylated receptor, which results in decoupling 
of the G protein and subsequent endocytosis 10,11. The receptors are then either degraded 
or recycled back to the plasma membrane.  
Chemokine receptors play an important role in the immune response by directing 
the migration of T lymphocytes to the site of infection. In the case of inflammation, the 
chemotactic response of immune cells is in response to a chemokine gradient that is 
created from the site of infection 7. Due to the importance of CCR5 and CXCR4 in the 
immune response, these receptors have been hijacked by immune deficiency viruses and 
cancer to facilitate disease progression12. The human immunodeficiency virus (HIV) 
requires CCR5 or CXCR4 as a co-receptor along with CD4 for viral entry into the host 
cell13-15. The use of either CCR5 or CXCR4 as a co-receptor for viral entry is dependent 
on the stage of the virus. CCR5 is reported to be the primary co-receptor, whereas 
CXCR4 is used in later stages of the virus 16. The discovery of the role of CCR5 and 
CXCR4 in HIV entry has made these receptors important pharmaceutical targets.  
The first proof-of-concept HIV-1 entry blocker was the small molecule CXCR4 
antagonist, AMD310017, which led to the development of CCR5-targeted entry blockers 
18. Maraviroc, a CCR5-specific small molecule, is the first patient approved GPCR-
specific HIV-1 entry inhibitor 19. Several of the GPCR-specific HIV-1 therapeutics that 
failed drug trials are often used as experimental tools to probe receptor function.  One 
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example is the conformationally sensitive antibody 2D7, which binds to an extracellular 
epitope on CCR5 20. 2D7 binds to the native structure of CCR5 and is a common tool to 
determine if CCR5 is correctly folded 21. A cyclic-peptide called T140, a CXCR4 
inhibitor, is another popular investigative tool that was identified due to its anti-HIV 
activity 22. For instance, an analogue of T140 was used to stabilize CXCR4 for 
crystallographic studies 23. Pepducins are another class of GPCR ligands that are 
interesting experimental tools and have shown therapeutic potential. Pepducins are 
palmitoylated peptides with agonist or antagonist potential, whose sequence mimics that 
of an intracellular loop of the target receptor 24. A CXCR4-specific pepducin, ATI-2341, 
mimics intracellular loop 1 of CXCR4 and is reported to be a CXCR4-agonist 25. 
Investigating the mechanism of action of ATI-2341 is important for the development of 
these ligands as GPCR therapeutics in addition to providing insight into the role of 
receptor intracellular loops for GPCR function. GPCR therapeutic agents are useful tools 
to study the structure and function of receptor signaling complexes.  
  
1.1.2. Importance of GPCR-ligand Interactions 
 
GPCRs are regulated by ligands of various sizes and structures. Some are peptides 
or small proteins, such as hormones and chemokines, while others are small molecules, 
like neurotransmitters, odorants, and pharmaceutical drugs. The mechanism of how a 
ligand binds to a GPCR and elicits a specific intracellular response is still unknown, 
although it has been well described that binding of a ligand on a GPCR results in a 
conformational change in the receptor’s structure. Receptor activation was originally 
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viewed as a ‘two state model,’ which described GPCRs to only have two conformations, 
active and inactive 26. Recent research has shown that the downstream signaling 
characteristics of a receptor are dependent on the identity of the bound ligand, suggesting 
the receptor has multiple conformational states 27,28. Investigating the functional 
selectivity of these conformational states will provide information about formation of the 
ternary complex, which includes a ligand, receptor, and G protein, and rationale for 
future drug design.   
Determining the structure of GPCR complexes is important for developing 
GPCR-specific small molecule therapeutics and biologicals29. Some GPCR-targeted 
drugs bind to orthosteric sites and inhibit the binding interactions with endogenous 
agonist ligands that are necessary to form productive signaling complexes.  However, 
GPCR-mediated signaling can also be affected by allosteric modulators30,31. Targeting 
potential allosteric sites on GPCRs opens up new avenues for structure-based drug 
design29. To facilitate future drug development and to understand the mechanism of 
action of existing drugs it is important to identify the binding sites of both orthosteric and 
allosteric GPCR modulators32,33. However, it is not straightforward to identify the precise 
binding sites and mechanisms of action of GPCR ligands. For example, GPCRs bound to 
antagonists or agonists are known to display different packing within the 7-helix bundle, 
and receptor activation proceeds through a series of agonist-GPCR conformations. In 
addition, computational predictions suggest that binding of various antagonists to CCR5 
stabilize different packing within the 7-helix bundle, which might lead to changes in 
function (e.g., coupling to β-arrestin or G protein) 34. The focus of this thesis project is on 
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the optimization and application of a chemically-precise technique in live cells, involving 
photoactivatable crosslinkers, to define a ligand-binding site on a GPCR.  
 
1.2. Probing GPCR-Ligand Interactions with Targeted Photoactivatable 
Crosslinkers  
Adapted	   from	   Grunbeck,	   A.	   and	   Sakmar,	   T.P.	   “Probing	   GPCR-­‐Ligand	   Interactions	  
with	  Targeted	  Photoactivatable	  Crosslinkers,”	  in	  preparation.	  
 
Photoactivatable crosslinking reagents have been used to study binding 
interactions within biological systems since the 1960s.  Westheimer and colleagues 
pioneered early work by applying photoreactive molecules to map an enzyme’s active 
site 35.  One of the advantages of using photoactivatable probes in a biological system is 
they react instantaneously with surrounding chemical bonds upon photolysis 36.  The 
ability to photoactivate a crosslinker reagent allows, at least in principle, for control over 
“when and where” a crosslinking reaction takes place. Therefore, these reagents enable 
the investigation of the structures of transient complexes in a cellular environment, for 
example, which is not possible with standard chemical or crystallographic techniques. 
Most physiologically relevant GPCR-ligand complexes require the native plasma 
membrane environment for complex formation. Photolabile probes with high affinity for 
receptors under native conditions and with minimal alteration to the structure of the 




  	  
There are several different reagents that are reactive upon photolysis, but only a 
handful of these are stable within a biological environment. A few of the most common 
ones that have been used to study biological interactions include diazoacyl ester 35, aryl 
azide 37-39, benzophenone 40, and diazirine 41. Each of these molecules has their own 
inherent advantages and disadvantages, which have been described in detail elsewhere 
36,42,43. The primary characteristics that differ among these molecules and determine their 
effectiveness to probe biological interactions are size, reactivity, and stability.  Over the 
past forty years or so photocrosslinking reagents have been popular tools for the study of 
GPCR-ligand interactions. The two obvious general strategies for investigating GPCR-
ligand interactions with chemical crosslinkers are either by attaching the photoactivatable 
moiety to the ligand or to the receptor (Figure 1-2). In this section we will cover the 
methodologies that have been used to generate photoactivatable GPCR ligands, in 
addition to the recent advances in the site-specific incorporation of photogenerated 








  	  
 
Figure 1-2. A diagram demonstrating how photoactivatable crosslinkers have been used 
to investigate GPCR-ligand interactions. The top panel shows the four most commonly 
used photocrosslinking molecules to study biological systems. These groups have been 
used to study GPCR-ligand interactions in two ways either by incorporating them into the 
ligand or into the receptor. 
 
diazocarbonyl arylazide benzophenone diazirine
Photoactivatable Crosslinkers












  	  
 
1.2.1. Photoactivatable GPCR Ligands 
 
 Photoaffinity labeling is a potentially powerful technique for identifying the 
receptors for orphan ligands and for determining a ligand-binding site on a receptor.   To 
perform these studies an analogous ligand needs to be designed that contains a 
photoactivatable crosslinking moiety while retaining binding affinity to the cognate 
receptor. Photoaffinity ligands have been synthesized in several different ways depending 
on whether the ligand is a small molecule, a peptide, or a protein (Figure 1-3). In the 




  	  
 
Figure 1-3. An overview of the methods discussed to create photoaffinity GPCR ligands. 
(A) Some native small molecule ligands naturally contain photoreactive groups. Other 
photoreactive small molecule ligands are generated by chemically labeling a molecule 
with a heterobifunctional group or synthesizing a photoactivatable analogue from scratch. 
(B) Peptide ligands are labeled post-peptide synthesis through an enzyme catalyzed 
reaction or chemical modification. (C) Photoreactive peptide ligands are also created by 
synthesizing a peptide using natural amino acids derivatized with photocrosslinking 
groups or photoactivatable unnatural amino acids 
Photoreactive Small Molecule Ligand















































































  	  
1.2.1.a. Synthetic Small Molecule Ligand Analogues 
 Many of the native ligands for family A, or rhodopsin-like GPCRs, are small 
molecules.  For example, the prototypical GPCR rhodopsin serves as the dim-light 
photoreceptor in the rod cells and binds the chromophore 11-cis-retinal, which acts like a 
pharmacological inverse agonist. To create an analogue of a small molecule that contains 
a photogenerated crosslinker generally requires extensive organic synthesis, as was the 
case in studies to determine the binding site and orientation of 11-cis-retinal in the 
transmembrane core of rhodopsin. Several analogues of 11-cis-retinal were synthesized 
to contain a diazirine group as a substituent on the β-ionone ring 38. These molecules 
were characterized for their ability to regenerate opsin. Only one of the analogues was 
able to bind to opsin to regenerate a pigment and found to crosslink to opsin upon 
exposure to ultraviolet (UV) light. After further analysis the orientation of 11-cis-retinal 
was determined to be such that the β-ionone ring was directed towards TM helices 3 and 
6 39.  Crosslinking an 11-cis-retinal analogue to opsin is a classic example of how it is 
possible to retain binding of a small molecule ligand to its receptor after introducing a 
photocrosslinking group. In addition, this work demonstrates how synthetic ligand 
analogues can determine the absolute orientation of a molecule in the ligand-binding site 
of a receptor without extensive site-directed mutagenesis and ligand binding assays on 
receptor mutants, or a high-resolution crystal structure of a receptor-ligand complex.  
Rhodopsin is unique compared to many other GPCRs because it is found in large 
abundance within the disc membrane of the retinal rod cell and can be purified to 
homogeneity in detergent solution. Other receptors are expressed at much lower levels in 
the native tissues, which complicates their identification, isolation, and characterization. 
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In such cases, the development of photoaffinity ligands is advantageous to identify target 
receptors and probe ligand specificity. One particular demonstrative example is the 
identification of the sex pheromone receptor in the silk moth Antheraea polyphemus. 
Ganjian et al. synthesized a diazoacetate derivative of the sex pheromone, HDA, and 
demonstrated that this molecule retained 10% of the native activity of the pheromone 44. 
UV irradiation of the diazoacetate HDA analogue when bound to sensory hairs from the 
silk worm resulted in the identification of a 69-kDa membrane protein 45. Prior to this 
discovery the involvement of a membrane receptor in the sex pheromone transduction 
mechanism was only a theory.  
 
1.2.1.b. Native or Native-like Ligands 
 
Native ligands, in some cases, are able to crosslink without the addition of 
specific reactive functional groups.  For example, dopamine is an example of a native 
photoaffinity ligand.  Nishikori et al. were the first to discover that UV illumination of 
mammalian nervous tissues in the presence of dopamine led to the covalent attachment of 
dopamine to specific cellular proteins. Dopamine does not contain one of the common 
photoactivatable crosslinking groups, and this report proposed that the photocrosslink 
occurs between the oxygen in the catechol moiety of dopamine and an amino acid residue 
in the dopamine receptor. Through the use of dopamine as a photoaffinity probe 
Nishikori and colleagues were also able to apply [3H]-dopamine to quantify the amount 
of purified receptor and identify that the D1 and D2 dopamine receptors are co-expressed 
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in mammalian nervous tissues 46. Others followed up this study and used the photoactive 
properties of dopamine to determine that dopamine binds specifically to a 57-kDa protein 
subunit in striatal membranes that they suggested was the D1 dopamine receptor 47.  
There are many advantages to performing photocrosslinking studies when the native 
structure of the ligand is retained, especially with small molecule ligands where addition 
of even a small chemical group significantly alters the structure of the molecule.  
Some drugs are themselves photoactivatable crosslinkers without further 
modification, although efficiency of the photolysis and crosslinking can be very low. 
Members of the adrenergic receptor subfamily of GPCRs have been extremely popular 
drug targets because of their significance in regulating the cardiac, pulmonary and 
circulatory systems.  For example, the β-adrenergic receptors have been the focus of 
many photocrosslinking studies involving photoreactive drug analogues. Isoprenaline, a 
β-adrenergic receptor agonist used as a cardiac iontropic agent and pressor substance, is 
one example of a GPCR drug that has been shown to label covalently a receptor upon 
photolysis without further modification of the molecule 48.  Other β-adrenergic receptor 
antagonists, generally termed β-blockers, have required alternative syntheses to 
incorporate a photoreactive group, resulting in the development of a plethora of β-
adrenergic azide-containing 49-53 and diazirine-containing 54 probes. Obviously, the ideal 
probe ligand contains a photoreactive moiety at a location distinct from its 
pharmacophore so that pharmacological activity is maintained.  Such synthetic ligand 
tools have been useful for the study of the β-adrenergic, and other types of related 
receptors, and exemplify how a variety of different photocrosslinkers based on small 
molecule analogues of GPCR ligands can be used to study ligand-binding sites.  
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1.2.1.c. Derivatizing Peptide Ligands with Photoactivatable Groups  
 
 A large number of GPCRs are activated by endogenous peptide hormones, 
neuropeptides, or peptide-derived ligands (peptides that are post-translationally 
modified).  Peptide ligands that target GPCRs have been labeled with photocrosslinking 
groups post-synthesis either through enzyme-catalyzed reactions or chemical 
modifications. The application of modifying enzymes for labeling purposes provides 
unique specificity and allows for labeling at positions that cannot generally be targeted 
with chemical reagents. For example, Gorman et al. demonstrated the use of guinea pig 
liver transglutaminase for the attachment of aryl azides onto the γ-carboxamide of 
glutamine residues in peptide ligands. Novel substrates for transglutaminase were 
synthesized and then reacted with peptide ligands, such as substance P and glucagon 1-6 
55. This technique was also applied to generate a photosensitive calcitonin analogue using 
the transglutaminase substrate N-(β-aminoethyl)-4-2-nitroaniline. Photolysis of this 
calcitonin analogue when bound to T47D breast cancer cells led to the identification of an 
85-kDa calcitonin binding protein 56.  The photoaffinity probe in this example facilitated 
the identification of the calcitonin receptor, which had not been done previously due to 
difficultly in stabilizing the receptor-ligand interaction. 
 Heterobifunctional reagents are perhaps the most common and effective tools for 
crosslinking peptide ligands to their cognate receptors. These types of reagents can 
derivatize peptide ligands prior to receptor binding, or once the ligand-receptor complex 
is formed. The prototypical structure of heterobifunctional reagents commonly includes a 
chemical crosslinking group attached via a linker to a photoactivatable crosslinking 
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group.  Here we describe several examples of heterobifunctional molecules that have 
been used to study GPCR-ligand interactions. 
 Labeling of primary amino groups in peptide ligands, either at the free amino 
group at the N-terminus or at lysine residues, can be carried out in several different ways. 
N-hydroxysuccinimide ester or succinidmidyl containing molecules react with all 
accessible primary amines. The N-terminus of oxytocin was labeled specifically using the 
N-hydroxysuccinimide ester of 2-nitro-5-azidobenzoylglycine because no lysines are 
present in this peptide 57. In other cases where more than one primary amine is present, 
protecting groups need to be used to label only one position. The parathyroid hormone 
was labeled specifically on a lysine with succinimidyl p-(3-iodobenzoyl) benzoate by 
using an Fmoc-protecting group on the N-terminal residue 58. One reagent that 
specifically labels the ε-amino group of lysines without reacting with the free amino 
group at the N-terminus is 4-fluoro-3-nitrophenylazide. This reagent was shown to label a 
lysine in glucagon and the location of the photoactivatable group was characterized by 
Edman degradation 59,60. 
 Another common functional group found in peptides is a carboxyl group, but 
derivatizing peptides at carboxyls is uncommon due to the high abundance of Asp and 
Glu residues in most peptides.  In general, the greater the number of positions in a peptide 
that are labeled, the more difficult it is to purify a homogeneous analogue and the more 
likely it is that its binding to the receptor will be perturbed.  One reagent used for 
carboxyl group modification is N-(5-azido-2-nitrophenyl)-2-ethylenediamine. In one 
report, this reagent labeled the carboxyl groups on α-thrombin via a carbodiimide 
condensation reaction. The photoreactive α-thrombin derivative was not found to have 
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significantly altered binding to cell surface receptors. In addition, this ligand was found 
to crosslink specifically to a ~50-kDa receptor on mouse embryo cells 61. Alternatively, 
peptide ligands can also be derivatized on Trp residues. Trp residues can be specifically 
labeled with sulfenyl chloride reagents that react with the side chain indole ring. 
Glucagon and corticotropin are two examples of peptide hormones that have been labeled 
with 2-nitro-5-azidophenylsulfenyl chloride for photoaffinity studies 62,63.  
 Heterobifunctional reagents can also be added to a receptor-ligand complex after 
the complex is formed. In this scenario crosslinking should occur between the ligand and 
receptor of interest.  However, since these types of reagents tend to bind relatively non-
specifically, the results of positive crosslinks can be complex and difficult to interpret.  
Despite the obvious drawbacks and low signal-to-noise problem inherent in attempts to 
crosslink with non-specific reagents, the procedure can be relatively straightforward since 
tedious chemical synthesis of photoactivatable ligands is not formally needed.  Another 
advantage of this approach is that native complexes between ligand and receptor are 
formed before the crosslinking reaction and neither the ligand nor the receptor is altered 
before photolysis.  This strategy was used to crosslink glucagon to the glucagon receptor 
in rat liver membranes. The heterobifunctional crosslinking reagent 
hydroxysuccinimidyl-p-azidobenzoate was added to membranes that were pre-incubated 
with [125I]-glucagon. Photolysis resulted in the covalent crosslink of the labeled glucagon 
to a 53-kDa protein 64.  
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1.2.1.d. Introducing Photoreactive Side Chains into Peptide Ligands  
 
 Photoreactive molecules can also be introduced into peptide ligands during 
peptide synthesis through the incorporation of amino acid derivatives or unnatural amino 
acids (UAAs). This strategy enables the incorporation of the photocrosslinker at any 
position in the peptide, whereas derivatization post-synthesis depends on the location of 
an available functional group. Benzophenone has been introduced into GPCR ligands in 
both of these manners. One report derivatized a lysine precursor prior to peptide synthesis 
with p-benzoylbenzoic acid 65.  The benzophenone-labeled lysine was introduced into 
parathyroid hormone and calcitonin during peptide synthesis 66,67. Kauer et al. 
synthesized another benzophenone-containing UAA, p-benzoyl-L-phenylalanine (BzF) 
68,69. BzF has subsequently been used in the development of many GPCR-targeted 
photoaffinity ligands.  BzF scanning can be carried out where BzF is incorporated 
successively at each position of a peptide ligand analogue.  In one notable example, BzF 
scanning was carried out on Substance P, which led to the identification of two specific 
positions where BzF in the peptide sequence resulted in analogues that crosslinked to the 
NK-1 receptor 70. Additional analysis of the crosslinked complex using protease digestion 
and analysis of proteolytic products led to the identification of the location in the receptor 
where the crosslink occurred 71,72. The process of identifying the location of the crosslink 
in the receptor can be extremely involved and complicated and in most cases precise 
identification of the site of a crosslink is not technically possible. Therefore, newer 
strategies described later in this report have been devised to improve the likelihood of 
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identifying sites of crosslinking, which dramatically enhances the utility and sensitivity of 
crosslinking experiments.   
 The introduction of BzF into peptide ligands to create photoaffinity probes has 
been used commonly for the study of class B GPCRs, also known as the secretin- or 
glucagon-like receptors. The characteristic structure of class B GPCRs includes a 
medium length N-terminal domain, also referred to as the ectodomain, which is important 
for binding peptide hormones. Extensive photocrosslinking experiments have been 
performed to understand how a peptide hormone binds to its cognate ectodomain. For 
example, the binding of secretin analogues to the ectodomain of the secretin receptor has 
been studied in detail using crosslinking approaches 73. In these studies BzF was 
incorporated at various positions in secretin and the resulting [125I]-labeled analogues 
were characterized and crosslinked to the receptor in native membranes. The general 
location of crosslinking in the receptor was identified through extensive digestion of the 
covalent receptor-analogue ligand complex followed by detection of the [125I]-labeled 
fragment in the resulting peptide mixture using SDS-PAGE 74. To improve the 
localization of the crosslink site additional cyanogen bromide cleavage sites were created 
in the receptor using site-directed mutagenesis to introduce Met residues 75,76. A similar 
strategy was also used to study the binding interactions between the vasoactive intestinal 
peptide (VIP) and the human VPAC1 receptor 77-79. A molecular model of the VIP-
hVPAC1 complex was created using the NMR structure of VIP and the distance 
constraints identified from the crosslinking study 80. This study is a notable 
demonstration of how photocrosslinking data can be applied to create a more detailed 
model of a GPCR-ligand complex. 
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 An UAA containing an aryl azide, p-azido-L-phenylalanine (azF), has also been 
synthesized 81. Since this amino acid is unstable under the conditions required for peptide 
synthesis 82, another method was needed to incorporate azF into peptides. A precursor 
ion, L-4-nitrophenylalanine, was incorporated at the position of interest during synthesis 
and then the nitro group was coverted to an azido group through additional chemical 
reactions 83. This method has been used to create photoaffinity analogues of angiotensin 
II and kinins 84,85. 
 More recently derivatives of Leu and Met have been generated to contain a 
diazirine group. These amino acids are referred to as photo-Leu and photo-Met, 
respectively 86, and were originally created for the incorporation of photoreactive groups 
into proteins expressed in cells since they can be recognized by the endogenous tRNA 
synthetases for Leu and Met. Photo-Leu has been incorporated into pepducins to 
investigate their mechanism of action 31. This photocrosslinking study demonstrated that 
the pepducin agonist, ATI-2341, crosslinked to its cognate receptor CXCR4, but the 
exact site of the crosslink was not identified.  In the section that follows, we will discuss 
the methods available for the site-specific incorporation of photoactivatable crosslinkers 
into GPCRs to enable the identification or mapping of ligand-binding sites. 
 
1.2.2. GPCRs Engineered to Contain Photocrosslinkers 
 
 A complementary technique to the use of photoaffinity ligands is to introduce 
photoactivatable groups at specific positions in a GPCR itself. An advantage to 
performing crosslinking experiments from the orientation of the receptor is that the exact 
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site on the receptor of any potential covalent linkage is known in advance.  Since the 
receptor is much larger than the ligand for any GPCR-ligand complex, and since the 
general aim of crosslinking experiments is to map the binding site of a ligand to its 
receptor, knowing the site of origin for a crosslink and the receptor can be a tremendous 
advantage. In general, as with the case of derivatizing the GPCR ligand, there are also 
two methods for introducing the photoreactive group into the receptor – either derivatize 
the receptor post-translationally or incorporate the unique functional group during protein 
translation (Figure 1-4). These methods both rely on heterologous over-expression of 
engineered receptors in culture using now standard techniques of molecular biology as 
discussed below.   
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Figure 1-4. Techniques for introducing photocrosslinkers into GPCRs. (A) 
Photocrosslinking groups have been attached to a specific residue, such as cysteine, in a 
GPCR through chemical modification of the receptor after extraction from cells. (B) 
Photoactivatable crosslinkers have also been incorporated into GPCRs expressed in cells 
































  	  
1.2.2.a. Labeling Cysteines with Photocrosslinkers 
  
 One way to introduce a photocrosslinker into a GPCR is to use sulfhydryl 
chemistry and target the available Cys residues after the receptor has been expressed and 
purified. Since all known GPCRs contain multiple Cys residues, to attain specific 
labeling at only one site in the receptor requires that all other Cys residues need to be 
removed by site-directed mutagenesis. This technique was used to introduce an aryl azide 
at a specific Cys in rhodopsin with the photocrosslinking group N-((2-
pyridyldithio)ethyl-4-azidosalicylamide (PEAS). In this report, the binding interactions 
between rhodopsin and the G protein, transducin, were investigated 87. The receptor was 
first extracted from the cell membrane using detergent and bound to an immunoaffinity 
resin before being derivatized with the PEAS reagent.   In principle this strategy could 
also be applied to investigate ligand-receptor interactions as long as the labeling reaction 
did not alter an essential conserved disulfide bond on the extracellular surface of the 
receptor. However, removal of all but one reactive Cys residue, which can then be 
strategically situated as desired in the receptor sequence, is a painstaking process that can 
take years to accomplish. Many GPCRs have atleast one cysteine residue that is essential 
for the correct formation of a receptor’s tertiary structure. 88,89. In addition, many ligand 
binding events that lead to a ternary complex between receptor and G protein require the 
receptor to be in a native-like membrane environment. Incorporating the photoreactive 
group into a receptor during protein translation overcomes this limitation as discussed in 




  	  
1.2.2.b. Unnatural Amino Acid Mutagenesis 
 
 The strategy of using amber stop codon suppression to incorporate amino acids 
with unique functional groups into proteins expressed in cells was developed most 
notably by Peter G. Schultz and coworkers 90. This methodology involves the engineering 
of orthogonal suppressor tRNA and amino acyl tRNA pairs and was originally advanced 
primarily for use in E. coli expression systems. For photocrosslinking studies, the tRNA 
synthetases were developed for the two relevant UAAs, BzF and azF 91,92. Since these 
reports, the amber codon suppression technique has been adapted and enhanced in order 
to incorporate BzF and azF into GPCRs expressed in yeast 93,94 and mammalian cells 95,96.  
 The prototypical yeast GPCR, Ste2p, was the first yeast receptor reported to have 
an UAA incorporated at a specific site in the receptor. In this study BzF was introduced 
into Ste2p expressed in Saccharomyces cerevisiae 93,94. The Ste2p BzF mutants were then 
examined for crosslinking to the Ste2p peptide ligand, α factor. Several positions in the 
receptor were reported to result in covalent crosslinks to biotinylated α factor 93. This was 
the first example of a covalent crosslink between an engineered GPCR with UAAs and a 
ligand. 
 The introduction of UAAs into GPCRs expressed in mammalian cells was first 
demonstrated using rhodopsin and CCR5.  Heterologous expression of rhodopsin and 
CCR5 UAA mutants in HEK 293T cells resulted in the expression of functional receptors 
at the cell surface 95,97. In this dissertation, we report the application of BzF and azF to 
identify a ligand-binding interface on a GPCR, a technique we term targeted 
photocrosslinking. We describe how the complex of CXCR4 and the CXCR4-specific 
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inhibitor T140 was used to validate the targeted photocrosslinking strategy and how the 
data were evaluated using the crystal structure of CXCR4 bound to a homologous T140 
peptide, CVX15 23,98. In addition, we performed a second photocrosslinking study to 
investigate the binding site of the FDA-approved small molecule drug maraviroc on 
CCR5. This complex currently has no crystal structure available. The methods described 
in this report detail how to perform the targeted photocrosslinking experiments, in 
addition to various strategies for evaluating the functional activity and ligand binding 
properties of GPCRs in cells, membrane preparations, and detergent. We also discuss the 
steps that we have taken towards determining the mechanism of action of the CXCR4-
specific pepducin. Finally, we review the complementarity of photocrosslinking studies 
and crystallography and how we would like to develop further the targeting 
photocrosslinking technique to investigate the binding interactions between GPCRs and 




  	  
 
CHAPTER 2: Materials and Methods 
 
2.1 Reagents and Buffers  
 
Materials. All enzymes for molecular biology applications were purchased from New 
England Biolabs. Protein expression vectors were purchased from Invitrogen. Protease 
inhibitor tablets were purchased from Roche. The 1D4 antibody was purchased from 
National Cell Culture Center. 2D7 was purchased from BD Biosciences and 3A9 was 
from Ebiosciences. The His4 antibody was purchased from Sigma. The FLAG mAb was 
purchased from Sigma. 2D7 and 3A9 were labeled in house with Atto655. Alexa647-
MIP-1α was purchased from Almac group. Fluorescein-labeled maraviroc analogues, FL-
maraviroc and FL-MVC-bp, and T140 analogue containing BzF and labeled with 
fluorescein (FL-T140-BzF) were provided by Dr. Martin Teintze from Montana State 
University. Fluorescein-T140 (FL-T140) was synthesized by the Proteomics Facility at 
Rockefeller University. Secondary antibodies conjugated to horseradish peroxidase 
(HRP) were acquired from KPL Inc.. 
 
Buffers: 
Buffer N: 20 mM Tris-HCl (pH 7.0), 0.1 M (NH4)2-SO4, 10%(v/v) glycerol, 
0.07% cholesteryl hemisuccinate (CHS), 0.018% 1,2-dioleoyl-sn-glycero-3-
phosphocholine (DOPC), 0.008% 1,2-dioleoyl-sn -glycero-3-phospho-L-serine 
(DOPS), 0.33% n-dodecyl-β-D-maltoside (DM), and 0.33% 3-[(3-
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cholamidopropyl)-dimethylammonio]-1-propanesulfonate (CHAPS)99. 
 
Buffers for Preparation of Membranes: 
a. Buffer HL: 1 mM Tris-HCl pH 6.8, 10 mM EDTA, 0.1 mM PMSF, 10 
µg/mL Aprotinin + Leupeptin  
b. Buffer MP: 20 mM Tris-HCl pH 6.8, 150 mM NaCl, 1 mM MgCl2, 1 mM 
CaCl2, 10 mM EDTA, with or without 0.1 mM PMSF 
 Buffers for [35S]-GTPgS Binding Assay:  
a. Buffer R: 50 mM Tris-HCl pH 7.5, 5 mM MgCl2, 0.5 mM EDTA, 60 mM 
NaCl, 10 µM GDP, 0.1 mg/mL saponin, and 1 mg/mL BSA  
b. Buffer W: 10 mM Tris-HCl pH 7.5, 5 mM MgCl2, and 60 mM NaCl 
CHAPSO buffer: 1%	  CHAPSO	  (Affymetrix-­‐Anatrace)	   in	  50	  mM	  Tris-­‐HCL;	  pH	  
8.0,	  0.5	  mM	  EDTA,	  250	  mM	  NaCl,	  0.2	  mM	  PMSF 
Buffer X: 1X Hank’s Buffered Salt Solution (HBSS) with 20 mM HEPES pH 7.4 
and 0.2% BSA 
Buffer D: 50 mM HEPES pH 7.4, 1 mM CaCl2, 5 mM MgCl2, and 0.5% BSA 
Buffers for Zap1 Purification: 
a. Homogenization buffer: 40 mM Tris pH 8, 0.3 M NaCl, 5 mM 2-
mercaptoethanol, 2 mM PMSF, and protease inhibitors  
b. Buffer T: 25 mM Tris pH 8, 0.3 M NaCl, 20 mM imidazole, 0.5 mM 
TCEP, and 1% (v/v) Triton X 100 
c. Buffer C: 25 mM Tris pH 8, 0.3 M NaCl, 20 mM imidazole, 0.5 mM 
TCEP, and 20 mM Na Cholate 
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d. Buffer ND: 25 mM Tris pH 8, 0.3 M NaCl, 20 mM imidazole, and 0.5 
mM TCEP 
e. Buffer E: 25 mM Tris pH 8, 0.3 M NaCl, 0.5 M imidazole, and 0.5 mM 
TCEP 
f. Buffer G: 10 mM Tris pH 8, 0.15 M NaCl, and 0.5 mM TCEP 
Buffer M: 20 mM Tris pH 6.8, 0.1 M (NH4)2SO4, 0.6% POPC, 0.4% POPS, 1% 
CHAPS, and 0.37 mg/mL 1D5 peptide 




2.2.1. Site-directed mutagenesis and plasmid construction.  
Construction of the suppressor tRNA and BzF and azF amino-acyl tRNA synthetase 
plasmids were described previously 95. The human CXCR4 gene and human CCR5 are 
both in a pcDNA3.1(+) plasmid and contain a C-terminal 1D4-epitope, TETSQVAPA.  
Single site mutations and amber codons were introduced into CXCR4 and CCR5 using 
the Quikchange Lightning Site-Directed Mutagenesis kit (Stratagene). The plasmid used 
for expression of the Zap1 protein in E. coli is pE28-zap1. Construction of this plasmid 




  	  
2.2.2. Construction of CXCR4/CCR5 Chimera by PCR Splicing by Overlap Extension 
(SOEing).  
A CXCR4 chimeric construct was created by exchanging the sequence between residue 
Met 63 and Leu 78 with the homologous sequence in CCR5, which corresponds to the 
residues between Leu 55 and Leu 70. This construct was created through a splicing by 
overlap extension (SOEing) method, which involves generating DNA fragments with 
overlapping ends 90,101. Two DNA fragments encoding upstream of Met 63 and 
downstream of Leu 78 in CXCR4 were made by PCR amplifying the CXCR4 template 
plasmid using primers with the sequences CTTAAGCTTGTTACCATGGAGG and 
CTTTTGCAGTTTATCAGGACCAGGATGACCAATCCATTG for one fragment and 
primers GACATCTACCTGCTCCACCTGTCAGTGGCCGACC and 
CTGCAGAATTCTTAGGCG for the other. The DNA fragment encoding the region of 
CCR5 between residues Leu 55 and Leu 70 was created by PCR amplifying the CCR5 
template plasmid with TTGGTCATCCTGGTCCTGATAAACTGCAAAAGGC and 
GGCCACTGACAGGTGGAGCAGGTAGATGTCAGTC. The three DNA fragments 
were then spliced together with two additional PCR reactions. Each of these PCR 
reaction mixtures contained 1 µg of template plasmid, 5 µL of 10X PCR buffer, 2 µL of 
10 mM dNTPs, 1 µL of 50 µM primers, and 1 µL of Pfu Turbo in a total of 50 µL 
reaction volume made up in ddH2O.  The conditions for these PCR reactions involved 5 
minutes of denaturation at 95°C followed by 30 cycles of denaturation (30 sec., 95°C), 
annealing (1 min., 50°C or 55°C) and extension (1 min. or 2 min., 72°C). The final cycle 
had a 7 minute extension step at 72°C followed by DPN-1 digestion for 1 hour at 37°C. 
The final PCR product was then reacted with Taq polymerase for 10 minutes at 72°C. 
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This PCR product was then cloned into a pcDNA3.1 Topo TA vector.  The new vector 
was then transformed into top 10 cells and mini-prepped. The plasmid was then digested 
at HINDIII and EcoRI restriction sites and ligated into a pcDNA3.1 vector, which had 
also been digested with the same restriction enzymes. This CXCR4 construct where the 
intracellular loop 1 region has been replaced with the homologous sequence of CCR5 
from now on will be referred to as CXCR4_R5i1. 
 
2.3. Expression of GPCRs in HEK293T Cells 
 
2.3.1. Culturing of HEK293T Cells and Transfection of GPCRs.  
HEK293T cells were grown in Dulbecco’s Modified Eagle’s Medium (DMEM; 4.5 g/L 
glucose, 2 mM glutamine; Gibco) containing 10% FBS in a 5% CO2 atmosphere at 37°C. 
Twenty-four hours prior to transfection cells were split so they were at 70-80% 
confluency for the day of transfection. For transfection in a 10 cm2 plate, 3.5 µg of 
receptor plasmid DNA or empty vector for mock transfections was mixed with 10 µL of 
plus reagent and 750 µL of DMEM. In a second tube 17 µL of lipofectamine was mixed 
with 500 µL of DMEM. After a 15 minute incubation at room temperature the two tubes 
were combined and incubated for another 15 minutes before being brought up to a total 
of 4 mL with DMEM and added to the cells. The cells were then incubated with the 
transfection mixture for 4 to 6 hours at 37°C in a 5% CO2 atmosphere and then 
supplemented with 4 mL of DMEM containing 20% FBS. Twenty-four hours post-
transfection the cell media was then replaced with 8 mL of new DMEM media with 10% 
FBS. Cells were harvested or used in experiments 48 hours post-transfection. 
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2.3.2. Expression of CCR5 and CXCR4 Unnatural Amino Acid Containing Mutants in 
Mammalian Cells.  
CCR5 and CXCR4 UAA mutants were expressed as previously described for CCR5 and 
rhodopsin 95. Briefly, HEK293T cells were transfected with three cDNA simultaneously, 
which contained the genes for the receptor amber mutant, BzF or azF amino-acyl tRNA 
synthetase and suppressor tRNA. Transfections were performed using lipofectamine plus 
reagent (Invitrogen). The ratio of DNA in µg was 1:0.1:1 CXCR4:UAA 
synthetase:suppressor tRNA. For transfection in a 10 cm2 plate, 3.5 µg of receptor DNA 
were used with 10 µL of plus reagent and 17 µL of lipofectamine.  Transfections 
performed in a 6-well plate used a quarter of these amounts.  Four hours post-transfection 
the media was supplemented to have a final concentration of 10% FBS with or without 
0.5 mM BzF or azF in Dulbecco’s Modified Eagle’s Medium (DMEM; 4.5 g/L glucose, 2 
mM glutamine; Gibco). The cells were scraped 48 hours post-transfection in 1X 
Phosphate Buffered Saline (PBS) containing the protease inhibitors aprotinin and 
leupeptin and tested for receptor expression through a Western Blot analysis. 
Note: The GPCR UAA mutants express at significantly lower levels than 
wildtype receptor. To obtain similar expression levels of UAA mutants 
and wildtype receptor use approximately 1/20 or 1/25 the amount of 





  	  
2.3.3. SDS-PAGE and Western Blot Analysis.  
Cell pellets were lysed in 1% (w/v) n-dodecyl β-D-maltoside in 50 mM Tris-HCl at pH 
7.5 containing protease inhibitors for 1 hour at 4°C on a nutator. Following solubilization 
the lysate was spun at 20,000xg for 5 minutes. For immunopurification experiments, the 
supernatant fraction was bound to sepharose beads conjugated to the 1D4 antibody 
overnight at 4°C. Samples were eluted from the beads by shaking in 1X NuPAGE LDS 
sample buffer containing DTT for 1 hour at 37°C. The samples were then run on an SDS-
PAGE gel (NuPage Novex 4-12% Bis-Tris Gel) and then transferred to a polyvinylidene 
difluoride (PVDF) membrane for immunoblotting. PVDF membrane was blocked in 5% 
milk in 1X Tris Buffered Saline with Tween-20 (TBST) for 1 hour at 4°C on a shaker 
followed by incubation with primary and secondary antibodies diluted in 5% milk in 1X 
TBST. For detection of CCR5 or CXCR4, PVDF membranes were blotted with a 1D4 
mAb at a 1:5000 dilution followed by incubation with an anti-mouse antibody (1:10,000) 
conjugated to horseradish peroxidase (HRP). Molecules conjugated to fluorescein were 
detected using a polyclonal anti-fluorescein antibody (abcam; #ab19491) at a 1:3000 
dilution followed by a secondary antibody anti-rabbit-HRP (1:10,000). The membranes 
were then incubated in a chemiluminescent substrate (Thermo Scientific) prior to being 
exposed to HyBlot CL autoradiography film (Denville Scientific Inc.). 
Note: The anti-fluorescein antibody is very specific for fluorescein. The 
reactivity of this antibody is not dependent on the presence of an 
aminohexanoyl linker between the fluorescein moiety and the protein. 
This antibody will also recognize fluorescein-maleimide and proteins 
labeled with fluorescein-maleimide. Also, exposure of fluorescein to UV 
light does bleach the fluorescence, but this does not appear to affect the 
reactivity of the antibody with the fluorophore. 
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2.4. In vitro Functional Assays 
 
2.4.1. Fluorescent Ligand Binding to CCR5 on Beads.  
Biotinylated 1D4 antibody was pre-bound to streptavidin-conjugated magnetic 
Dynabeads (Invitrogen). Cf2th cells (NIH AIDS Research & Reference Reagent Program 
21) stably expressing CCR5 were solubilized in buffer N containing protease inhibitors. 
Lysate was sonicated with six 1 second pulses and then incubated on a nutator for 2 hours 
at 4°C. Lysate was then bound to the 1D4 Dynabeads for 30 minutes at 4°C. After the 
incubation the bead-lysate suspension was then split into 3 eppendorf tubes, beads were 
pelleted with a magnet, and supernatant was removed. To each tube 50 nM of Atto655-
2D7, Atto655-3A9 or Alexa647-MIP-1α was added. Samples were incubated on a nutator 
for 10 minutes at room temperature. Beads were then pelleted with a magnet, supernatant 
was removed, and samples were eluted from the beads with 5% sodium dodecyl sulfate 
(SDS) in 1X PBS. Eluted samples were transferred to a 384-well plate and the 
fluorescence was read on the envision plate reader (Perkin Elmer). A representative data 
set is shown in Figure 2-1. 
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Figure 2-1. Fluorescent ligand binding to CCR5 on beads. This figure is a representative 
data set measuring binding of fluorescently labeled ligands to CCR5 in detergent.  The 
three fluorescently tagged ligands used in this study were 2D7, a mAb that recognizes a 
conformational epitope on CCR5, 3A9, a mAb that recognizes a linear epitope at the N-
terminus of CCR5, and MIP-1α, one of the native chemokine ligands for CCR5. On the 
bar graph UB stands for unbound samples and E is for the eluted samples. Non-specific 
binding was measured by incubating the beads with detergent-containing buffer without 
CCR5. This graph shows that specific binding of 2D7 and 3A9 can be measured to CCR5 
in detergent using fluorescently labeled antibodies. No specific binding of MIP-1α was 
found to CCR5 containing samples, which agrees with other reports that binding of this 




  	  
2.4.2. Immunopurification of CCR5 by Conformationally Sensitive Antibody on 
Dynabeads.  
Protein G magnetic Dynabeads (Invitrogen) were transferred to an eppendorf tube and 
washed with 1X PBS. Bead suspension was then split between three or four eppendorf 
tubes. Beads were separated with a magnet and 200 µL of buffer N or 1X PBS was 
added.  To each tube 5 µg of the 2D7, 1D4, His4, or FLAG monoclonal antibodies were 
added and allowed to incubate for 20 minutes on the shaker (approximately 5 µg of 
antibody per approximately 0.2 mg of Dynabeads). Beads were separated with a magnet, 
supernatant was removed, and beads were washed with buffer N. In the case of using 
CCR5 in detergent, membrane preparations from CCR5 stably expressing cells were 
solubilized in buffer N with protease inhibitors for 3 hours at 4°C on a nutator. Lysate 
was spun down and supernatant was added to the prepared Dynabead samples. If CCR5 
containing NABBs were being used, the NABBs were prepared as described below and 
then added to the prepared Dynabeads. Samples incubated with beads for 1 hour at room 
temperature. Beads were then separated with a magnet, supernatant was removed, and 
samples were eluted from beads by shaking for 1 hour at room temperature in 1X 
NuPAGE LDS sample buffer (Invitrogen) diluted in buffer N. Unbound and eluted 
samples were then run on an SDS-PAGE gel, transferred to a PVDF membrane, and 
immunoblotted with the 1D4 antibody to look for the presence of CCR5. A representative 
data set is shown in Figure 2-2. 
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Figure 2-2. Immunopurification of CCR5 by 2D7 on magnetic Dynabeads. In this 
experiment CCR5 was solubilized in a detergent-containing buffer that had previously 
been reported to retain CCR5 in its native conformation.  This was measured by binding 
to the conformationally sensitive antibody 2D799. Here we also demonstrate that CCR5 in 
Buffer N can be immunopurified by 2D7. As a positive control CCR5 was also 
immunopurified with the 1D4 antibody, which recognizes a linear epitope at the C-
terminus of CCR5. A His4 antibody was used to determine non-specific binding of the 
receptor to the beads. The Western Blot shown is detected with the 1D4 mAb. The bands 
detected at approximately 37 kDa correspond to monomeric CCR5 and the bands 
detected above 50 kDa are the antibody heavy chain. The results from this experiment 
showed that the same amount of CCR5 was immunopurified with 1D4 and 2D7 and no 
background binding was seen with the His4 antibody. This suggests that CCR5 is in its 
native conformation in Buffer N. In addition this assay is a useful method for identifying 
whether CCR5 is correctly folded and for purifying correctly folded receptor from a 
heterogeneous solution of CCR5 conformations. 
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2.5. Functional Assays in Membrane Preparations 
 
2.5.1. Preparation of Membranes from HEK293T Cells.  
HEK293T cell pellets were lysed with buffer HL. Lysates were forced through a 23-
gauge needle, then 26-gauge needle on a 1 mL syringe 3 times. In TLS-55 centrifuge 
tubes (Beckman, reorder#: 347356), 1 mL of 35.5% (w/w) sucrose solution in buffer MP 
was added to each tube. The lysed pellets were slowly layered on top of the sucrose 
solution. Tubes were balanced by adding in extra buffer HL and then spun in the TLS-55 
rotor (SN# 2168) on the ultracentrifuge at 22,000 rpm at 4°C for 20 minutes with 
acceleration and deceleration both set to 5. Membrane layer was removed from tubes 
with a 23-gauge needle on a 3 mL syringe. Membranes were added to two TLA 100.3 
tubes (Beckman, reorder#: 326819) then 3.4 mL of buffer MP with PMSF was added to 
each tube and tubes were balanced with additional buffer MP with PMSF. Tubes were 
centrifuged in a TLA 100.3 rotor (SN# 3583) at 60,000 rpm at 4°C for 30 minutes. 
Supernatant was poured off and pellets were resuspended in buffer MP with PMSF (3.5 
mL) using a 1 mL syringe with a 27-gauge needle. Tubes were then centrifuged again in 
a TLA 100.3 rotor at 60,000 rpm at 4°C for 30 minutes. Each pellet was then resuspended 
in buffer MP and protein amounts were quantified using the Biorad DC protein assay. 
Membranes were suspended at a protein concentration of approximately 1.83 mg/mL and 




  	  
2.5.2. Quantifying CCR5 Expression in Membrane Preparations or Cells with 
fluorescein-maraviroc (FL-maraviroc).  
For the membrane preparation experiments, an aliquot of CCR5-containing membranes 
and untransfected cell membranes was thawed. Membranes were combined with buffer N 
containing 100 nM FL-maraviroc in the presence or absence of 10 µM TAK-779. 
Samples were resuspended and put at 4°C on a nutator overnight. For the cell-based 
experiments, the cells were first solubilized in buffer N for 3 hours at 4°C and then lysate 
was spun down in an ultracentrifuge tube at 14,000 rpm for 20 minutes. The lysate was 
then incubated with 100 nM FL-maraviroc overnight at 4°C. After incubation with FL-
maraviroc the samples were spun down and the supernatant was bound to sepharose 
beads conjugated to the 1D4 antibody at 4°C on a nutator overnight. After 24 hours the 
samples were transferred to Ultrafree-MC tubes and the beads were washed with buffer 
N. The samples were eluted from the beads in 1% SDS in 20 mM Tris-HCl pH 7.5 by 
shaking for 1 hour at room temperature. The tubes were then spun down and the elution 
was transferred to a 96-well black round bottom plate and read on the CytoFluor II 
fluorescence multi-well plate reader (ex: 485nm; em: 530nm). FL-maraviroc dilutions 
were made to create a standard curve and the amount of specifically bound FL-maraviroc 
was calculated. A representative data set is shown in Figure 2-3. 
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Figure 2-3. Quantifying CCR5 expression with a fluorescein-maraviroc analogue. We 
have optimized a method for quantifying CCR5 expression using a fluorescein-labeled 
maraviroc analogue (FL-maraviroc). Panel (A) shows that we can measure the amount of 
FL-maraviroc that is specifically bound to CCR5 in membrane preparations through 
competition with another CCR5 inhibitor TAK-779. The amount of non-specific binding 
detected in the competition experiment also agrees with the amount bound to membrane 
preparations that do not contain CCR5. Panel (B) displays the amount of FL-maraviroc 
that was specifically bound to CCR5-containing lysate, which also demonstrates that 
CCR5 in buffer N is still able to bind FL-maraviroc. These results determine that FL-
maraviroc can be used to quantify the amount of CCR5 present in a sample. 
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2.5.3. [35S]-GTPgS Binding to CCR5 and CXCR4 containing Membrane Preparations. 
A 100 nM stock of [35S]-GTPgS was made up in buffer R. For each condition to be tested 
an eppendorf tube was made up with a 50 µL solution containing 10 µg of membrane 
protein, the ligand of interest, and 2 nM [35S]-GTPgS. Reactions incubated for 15 minutes 
in a 30°C water bath and then 49 µL of the reaction was transferred to 2.5 mL of cold 
buffer W on a nitrocellulose membrane. Solutions were then vacuumed filtered through 
the membrane and washed three more times with cold buffer W. Nitrocellulose 
membranes were then transferred to vials with Ecoscint A scintillation fluid (National 
Diagnostics) and counted on a LKB Wallac Beta Liquid Scintillation Counter. A 
representative data set is shown in Figure 2-4. 
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Figure 2-4. Ligand induced [35S]-GTPγS binding to CCR5- and CXCR4-containing 
membrane preparations. We were able to measure chemokine receptor dependent G 
protein activity using a radioactive non-hydrolyzable GTP analogue. (A) Membrane 
preparations containing CCR5 when treated with RANTES, a CCR5 agonist, resulted in 
an increase in the amount of GTPγS bound to the membranes. Alternatively, when these 
membranes were treated with maraviroc, a CCR5 inverse agonist, there was a decrease in 
the amount of GTPγS bound to the membranes. (B) The same trend was also seen with 
CXCR4-containing membrane preparations when they were treated with SDF-1α, a 
CXCR4 agonist, and T140, a CXCR4 inverse agonist. This is a proof of concept 




  	  
2.6 Cell-Based Functional Assays 
 
2.6.1. High-throughput Calcium Flux Assays.  
Twenty-four hours post-transfection, cells were plated onto a poly-D-lysine coated 384-
well plate at 20,000 cells per well in 20 µL of DMEM with 10% FBS. The plate was spun 
down for 5 minutes at 700 rpm after plating and put back into a 37°C incubator with a 
5% CO2 atmosphere.  The next day the cells were loaded with Calcium 4 dye (Molecular 
Devices) for 1 hour at 37°C. Calcium 4 dye solution was made up with 0.4% BSA and 20 
µL was loaded per well. Ligand dilutions were made up in buffer X. Fluorescence 
measurements and ligand additions were performed using the FlexStation II (Molecular 
Devices).  The change in fluorescence detected upon ligand addition was plotted versus a 
log function of the ligand concentration. The plot was then fit to a sigmoidal function 
using Origin Graphing Software and the EC50 values were calculated.  
 
2.6.2. Cell Surface Enzyme-Linked Immunosorbent Assay (ELISA).  
Transfected cells were split 24 hours post-transfection into black clear bottom 96-well 
plates pre-coated with poly-D-lysine. The next day the media was changed on the cells to 
DMEM without FBS and incubated for 1 hour at 37°C in the incubator. Cells were then 
washed once with 100 µL per well of 1X Dulbecco’s PBS (DPBS) containing calcium 
and magnesium. Cells were fixed with either paraformaldehyde at room temperature for 
15-20 minutes or MeOH for 5 minutes at 4°C. The fixed cells then incubate with primary 
antibody in 1X DPBS containing 0.5% BSA on ice for 1 hour. The primary antibodies 
were used at the following dilutions 1D4 (1:2000), 2D7 (1:500), and 12G5 (1:2000). 
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After incubation the cells were washed twice with 1X DPBS with 0.5% BSA. The 
secondary antibody anti-mouse conjugated to horseradish peroxidase was then added to 
the cells at a 1:2500 dilution in 1X DPBS with 0.5% BSA and incubated for 30 minutes 
at room temperature. The cells were washed three times with 1X DPBS with 0.5% BSA 
and then the amplex-red solution was added to the wells. The amplex-red solution was 
made up with 4.5 mL of 1X PBS, 0.5 mL of 20 mM H2O2, and 50 µL of 10 mM amplex 
red reagent (Molecular Probes). The cells incubated for 15 to 20 minutes at room 
temperature with the amplex red solution and then the plates were read on the CytoFluor 
II fluorescence mult-well plate reader (ex: 530nm, em: 590nm).  
2.6.3. [125I]-RANTES Binding to CCR5 Expressing Cells.  
(This work was done in collaboration with Dr. Reem Berro at Weill Cornell Medical 
College in Dr. John Moore’s Lab.) Two days post-transfection cells were scraped, 
washed once with 1X DPBS and then resuspended in 1X DPBS. Cells were then counted 
and transferred to a 96-well V-bottom plate so that each well contained 800,000 cells. 
The plate was then spun down at 1900 rpm and the media was aspirated. The cells were 
then resuspended in 50 µL of buffer D with or without a known concentration of 
vicroviroc. The cells incubated with vicroviroc at room temperature for 30 minutes and 
then [125I]-RANTES was added for a final concentration of 400 pM or otherwise 
indicated. The cells incubated with [125I]-RANTES for 1 hour at room temperature. The 
plate was then spun down at 1900rpm for 2 minutes and washed four times with 200 µL 
of 1X DPBS. After the last wash the cells were resuspended in 200 µL of 1X DPBS and 
transferred to scintillation vials and read on a Packard Gamma Counter Model 5530. A 
representative data set is shown in Figure 2-5 103. 
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Figure 2-5. [125I]-RANTES binding to CCR5 expressing cells. In this experiment we 
measured the IC50 of vicriviroc to CCR5 expressed in cells by quantifying the amount of 
[125I]-RANTES that was displaced by a specific concentration of vicriviroc. Radiolabeled 
ligand binding is a common technique used in the GPCR field to measure ligand-binding 
affinity. Here we demonstrate that we can perform these experiments on live cells. This 
assay was used to measure the binding affinity of vicriviroc to CCR5 mutants in a 




  	  
 
2.7. CCR5 NABBs  
 
2.7.1. Expression and Purification of Zap1.  
This protocol is described in detail elsewhere 100.  In brief, the zap1 construct (pE28-
zap1) was expressed in BL21 (DE3) rosetta2 cells. The cells were harvested after 
reaching an OD600 ~1.2. Cells pellets were resuspended in homogenization buffer and 
then put through a French press. The cell extract was incubated with 1% Triton X-100, 
DNAse I, and 5 mM MgSO4 for 30 min. and then spun down on a Beckman centrifuge 
for 45 minutes at 16,500 at 4°C. The supernatant was filtered with a 0.45 or 0.65 µm 
syringe filters and then put into a super loop to be separated on an AKTA explorer FPLC. 
The supernatant was loaded onto a Ni column, washed once with buffer T, washed with 
10 column volumes of buffer C and 10 column volumns of buffer ND. Zap1 was eluted 
from the Ni column with an increasing gradient of Buffer E over 10 column volumes. 
The zap1 fractions were collected from the Ni column and concentrated to about 5 mL 
using an Amicon Ultra. The concentrated zap1 was then loaded into a superloop and 
injected onto a Superdex 200 26/60 pg column.  The sample was eluted from the column 
with buffer G. Fractions of zap1 were collected and a SDS-PAGE gel was run to 
determine which peak contained monomeric full-length zap1. 
 
2.7.2. Incorporating CCR5 into Nanoscale Apolipoprotein Bound Bilayers (NABBs). 
This procedure was adapted from Banerjee et al. and Knepp et al. 100,104. Forty-eight 
hours post-transfection of HEK293T cells with CCR5, the cells were harvested and 
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solubilized in buffer N. Lysate was then centrifuged and the supernatant was bound to 
sepharose beads conjugated to the 1D4 mAb overnight at 4°C. The next day the beads 
were washed three times with buffer N and then eluted from the beads in two 30-minute 
elutions with buffer M. The purified CCR5 was then combined with zap1 and POPC, the 
ratio of zap1 to lipids was 1:75, in a buffer containing 1.5% sodium cholate, 0.33% DM, 
15 mM Tris-HCl (pH 7.0), 75 mM (NH4)2SO4, and 7.5% glycerol. This mixture 
incubated for 30 minutes on ice and was then put on a 1 mL column packed with 
detergent-removing resin (Pierce). The NABBs were then eluted from the column with 
NABB buffer, fractions were collected, and NABB containing fractions were identified 
by measuring the absorbance at 280 nm. 
 
2.8. Evaluation of Antibodies 
 
2.8.1. Dot Blot Analysis of Anti-Rhodamine Antibodies.  
A 3 in.2 piece of PVDF membrane was washed in MeOH and then allowed to air dry. 
When the membrane was dry 5 µL of rhodamine-labeled peptide samples were pipette 
onto the membrane in a grid drawn with a pencil. Peptide dilutions were made in ddH2O. 
The membrane was then allowed to air dry and then blotted with primary and secondary 
antibodies as described for Western Blot analysis. The primary anti-rhodamine antibodies 
were all used at a dilution of 1:2000. The three antibodies tested in this manner were a 
mouse monoclonal antibody from Acris (cat.#: AM08431PU-N), a rabbit polyclonal 
antibody from Molecular Probes (cat.# A-6397), and a mouse monoclonal antibody from 
Abcam (cat.# ab9093). A representative data set is shown in Figure 2-6. 
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Figure 2-6. Dot blot analysis of anti-rhodamine antibodies. It is important to have a 
sensitive detection antibody for the photocrosslinking experiments. Here is one example 
of how we test an antibody’s reactivity through a dot blot analysis. A dilution series of 
two tetramethylrhodamine (TAMRA) labeled peptides were bound to a PVDF membrane 
using a dot blot apparatus. Peptide #1 is a TAMRA-labeled analogue of the pepducin 
ATI-2341. Peptide #1 is conjugated directly to TAMRA via an amide bond whereas 
peptide #2, TAMRA-glucagon, contains an aminohexanoyl linker between the TAMRA 
and the peptide. The results show that the Abcam anti-rhodamine antibody (cat.# ab9093) 
is able to detect peptide #2, but not peptide #1 on a dot blot. This suggests that a linker 
between the fluorophore and peptide is required for detection of the fluorophore when it 
is directly conjugated to a peptide. This might indicate that the antibody is unable to react 
with the fluorophore on peptide #1 due to steric hindrance by the peptide. 
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2.8.2. Evaluation of Antibodies to Heterotrimeric G protein Subunits, Chemokines, and 
HIV Envelope Protein (gp120).  
Antibodies reacting with heterotrimeric G protein subunits, chemokines, and gp120 were 
evaluated either by dot blot analysis or SDS-PAGE followed by Western Blot detection. 
For evaluation of G protein antibodies, HEK293T cell pellets or membrane preparations 
were solubilized in 1% Triton X-100 with protease inhibitors for 1 hour at 4°C. Lysates 
were then run on an SDS-PAGE gel, which was then transferred to a PVDF membrane 
for Western Blot analysis. The primary antibodies used in this study are described below. 
The secondary antibodies were all directly conjugated to HRP and used at a dilution of 
1:10,000. All primary G protein antibodies were obtained from Santa Cruz 
Biotechnology Inc.. A goat polyclonal antibody to Gαi-1/2/3 (cat.# sc-26716) was used at a 
1:200 dilution. A rabbit polyclonal antibody to Gαi-1 (cat.# sc-391) was used at a 1:50 
dilution. A rabbit polyclonal antibody to Gβ (cat.# sc-378) was used at a 1:3000 dilution. 
The Western Blot evaluating the G protein antibodies is shown in Figure 2-7B. The bands 
detected at approximately 37 kDa correlate to the heterotrimeric G protein subunits.  The 
Gαi-1/2/3 antibody did not detect any proteins suggesting either it does not recognize any 
proteins in these samples or the protein levels are too low to detect. The Gαi-1 antibody 
detected protein only in the whole cell lysate sample and not in the membrane 
preparations. This might suggest that this G protein alpha subunit is not bound to the 
membrane or there is not enough protein present to detect with this antibody. The Gβ 
antibody was able to detect the G protein beta subunit in all lanes, which indicates that 
the G protein beta subunit is present in all of these samples. We were unable to determine 
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what the bands at the higher molecular weights are. It is possible that they could be 
aggregated protein samples or complexes that did not dissociate in the denaturing gel.  
 Antibodies that react with gp120, an HIV envelope protein, were obtained from 
Dr. John Moore’s Lab at Weill Cornell Medical College. The Moore Lab also provided 
purified JRFL gp120. The pure gp120 was diluted in 1X NuPAGE LDS sample buffer 
containing 10 mM DTT and ~1% DM. A known amount of gp120 was then run on a 
SDS-PAGE gel, transferred to a PVDF membrane, and immunoblotted with the 
following primary antibodies. The mouse PA-1 antibody (Progenics Pharmaceuticals 
Inc.) was used at a dilution of 1:1000, sheep D7324 antibody from Aalto Bioreagents was 
used at a dilution of 1:133, and mouse ARP3119 (National Institute for Biological 
Standards and Control (NIBSC), Centralised Facility for AIDS Reagents, Hertfordshire, 
UK) was used at a dilution of 1:2000. The appropriate secondary antibody conjugated to 
HRP was used for detection at a dilution of 1:10,000. An antibody to the chemokine 
SDF-1α was tested with the same procedure. This antibody was a rabbit polyclonal 
antibody from Cell Signaling (cat.# 3740) and was used at a dilution of 1:1000. A 
representative data set is shown in Figure 2-7. 
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Figure 2-7. Evaluation of antibodies to G protein subunits, chemokines and gp120. Here 
we have evaluated the ability of several commercial antibodies to detect purified gp120 
(A), G protein subunits from cell extract (B), and SDF-1α obtained from a commercial 
source (C) on a Western Blot after being run on a denaturing gel. In panel B, sample 1 is 
lysate from HEK 293T cells, sample 2 is solubilized membranes prepared from HEK 
293T cells, and sample 3 is solubilized membranes prepared from HEK 293 T cells 
transfected with WT rhodopsin.  The purpose of testing these antibodies was to determine 
whether they could be used to identify crosslinks between a receptor and one of these 
binding partners. These blots display the reactivity of each of the antibodies with the 




  	  
2.9. Photocrosslinking Studies 
2.9.1. Photocrosslinking of Rhodamine-labeled Pepducin to CXCR4.  
(This work was done in collaboration with Anchor Therapeutics in Cambridge, MA 31.) 
HEK293T cells heterologously expressing CXCR4 were incubated with 3 µM of a 
rhodamine-labeled analogue of ATI-2341 containing photo-leucine at one position (ATI-
2766) in 1X Hank’s Buffered Salt Solution (HBSS; pH 7.5) containing 20 mM HEPES 
and 0.2% BSA for 10 minutes at 37°C. Following incubation the pepducin-containing 
buffer was aspirated and 1.5 mL of HBSS buffer with 20 mM HEPES and 0.2% BSA was 
added. The plate was put under a Maxima ML-3500S UV-A light (Spectronics 
Corporation) for 5 to 15 minutes and then the cells were scraped and transferred to an 
eppendorf tube. The cells were spun down and washed three times with 1 mL of 1X 
DPBS containing protease inhibitors. The cells were solubilized in 1 mL of CHAPSO 
buffer for 1 hour at 4°C in the dark. The lysate was spun down and the supernatant was 
transferred to one tube for SDS-PAGE analysis and another tube for immunopurification 
with 1D4 sepharose beads. The lysate nutated with the 1D4 sepharose at 4°C in the dark 
overnight and the next day the unbound lysate was removed and beads were washed three 
times with CHAPSO buffer. Samples were then eluted from the beads with 1% SDS for 1 
hour at 37°C on a shaker. Both the lysate and immunopurified samples were run on a 
SDS-PAGE. After the gels were run they were imaged on a typhoon 9400 fluorescence 
scanner and then transferred to a PVDF membrane for immunoblotting with the 1D4 
antibody.  (typhoon settings: emission 580 Bp 30 Cy3, TAMRA, Alexafluor546; PMT 
560; laser Green 532) 
Note: To detect a photocrosslink between a GPCR and a rhodamine-
labeled ligand using fluorescence requires significantly more crosslinked 
complexes than using the anti-fluorescein antibody to detect a fluorescein 




  	  
2.9.2. Photocrosslinking of Fluorescein-tagged (FL-tagged) Ligands to Heterologously 
Expressed GPCRs in live cells.  
HEK293T cells expressing WT receptor or receptor UAA mutants were incubated with 
50 or 100 nM of the FL-tagged ligand in 1X HBSS pH 7.5 containing 20 mM HEPES 
and 0.2% BSA for 10 minutes at 37°C in a 5% CO2 atmosphere. For competition studies, 
the FL-labeled ligand was co-incubated with the competitor at the concentration 
indicated. Following incubation the cells were put under a Maxima ML-3500S UV-A 
light (Spectronics Corporation) in a 4°C cold room on ice for 15 minutes or otherwise 
indicated. After UV light exposure the cells were scraped in 1X PBS containing the 
protease inhibitors aprotinin and leupeptin and spun down in a tabletop centrifuge at 
3000xg for 5 minutes. Cell pellets were then solubilized in detergent and analyzed by 
SDS-PAGE and Western Blot detection as described above. 
 
2.9.3. Photocrosslinking of Cells Expressing CCR5 UAA mutants to [3H]-maraviroc. 
Two days post-transfection, HEK293T cells were suspended in 1X DPBS. Cells were 
then spun down and resuspended in 1X HBSS pH 7.5 containing 20 mM HEPES with 
0.2% BSA and 100 nM [3H]-maraviroc. Cell suspensions were then incubated for 2 hours 
at 37°C on a nutator. After the incubation, cell suspensions were transferred to a 24-well 
plate and exposed to a Maxima ML-3500S UV-A light (Spectronics Corporation) in a 
4°C cold room on ice for 15 minutes. After UV light exposure, cells were transferred to 
eppendorf tubes, pelleted, and supernatant removed. Cell pellets were then stored at -
20°C until further analysis. For analysis, cell pellets were solubilized in detergent and the 
receptors were immunopurified from the lysate using the 1D4-sepharose. The purified 
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samples were then separated on a SDS-PAGE gel and detected on a Western Blot with 
the 1D4 antibody as described above. 
 
2.9.4. Quantification of [3H]-maraviroc Bound and Crosslinked to CCR5 UAA 
mutants.  
After the PVDF membrane was exposed to film, the membrane was then cut into 
segments to quantify the amount of tritium present. The membrane was cut between each 
lane to separate each sample; in addition, each sample was cut into three different 
molecular weight segments as specified.  Each of these membrane segments were then 
transferred to individual vials with scintillation fluid and counted on a LKB Wallac 1209 
Rackbeta Liquid Scintillation Counter (Perkin Elmer). To quantify the amount of [3H]-
maraviroc that was bound to each of the CCR5 UAA mutants, 15 µL of the original 
eluted sample from the 1D4 mAb sepharose beads was transferred directly into a vial 
with Ecoscint A scintillation fluid (National Diagnostics). All of the scintillation vials 
were mixed thoroughly before being counted on the LKB Wallac Beta Liquid 
Scintillation Counter. Each vial was counted over 10 minutes. After counting, the counts 
per minute (cpm) per cm2 of PVDF membrane was then calculated for each membrane 
segment by dividing the cpm for a particular sample by the area of the membrane 
segment in cm2.  The amount of [3H]-maraviroc each CCR5 UAA was able to bind was 
normalized to the other mutants by setting the WT sample as 100% and then calculating 
for the UAA mutants what percentage they were of WT.  
Note: It is important to perform the 1D4 Western Blot using the same 
PVDF membrane that is cut for beta-scintillation counting because all the 
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wash steps involved in performing the Western Blot remove all the [3H]-
maraviroc that is non-specifically bound to the PVDF membrane. There is 
a lot of [3H]-maraviroc carried over to the SDS-PAGE because any 
uncrosslinked maraviroc stays bound to CCR5 until the receptor becomes 
denatured on the SDS-PAGE gel. A tritium gradient is then detected on 
the PVDF membrane if no washing steps are performed before the 
scintillation counting. The washing steps used for the Western Blot works 
well to remove a small molecule that does not bind well to the PVDF 
membrane, but other steps may need to be taken if the tritiated ligand has 




  	  
2.10. Preparation and Digestion of CCR5 for MS Analysis 
 
2.10.1. Cyanogen Bromide (CNBr) and Trypsin Digestion of CCR5 and CCR5 
Crosslinked Complexes.  
HEK293T cells were transfected with WT CCR5 as described above. Forty-eight hours 
post-transfection the cells were scraped in 1X DPBS with aprotinin and PMSF. The cell 
pellet was resuspended in 6 mL of 1X HBSS pH 7.5 with 20 mM HEPES in the presence 
or absence of 100 nM Fluorescein-maraviroc-BzF (FL-MVC-BzF) and 0.2% BSA. Cell 
suspension was put into the 37°C CO2 incubator on a nutator for 2 hours. After 
incubation the cell suspension was transferred to a 24-well plate and put under a Maxima 
ML-3500S UV-A light for 15 minutes. The cell suspension was then transferred back to a 
falcon tube, spun down, and supernatant removed. The cell pellets were solubilized in 1% 
DM in 20 mM Tris pH 7.0 with protease inhibitors for 1 hour at 4°C and sonicated with 
six 1 second pulses. The lysate was then spun down at full speed on a tabletop centrifuge 
and the supernatant was bound to 1D4-sepharose beads overnight at 4°C. The next day 
the beads were washed threes times with 1% DM in 20 mM Tris pH 7 and samples were 
eluted with 1D5 peptide in 1% DM in two 1 hour elutions in an eppendorf spin filter on 
ice. The purified receptor was reduced by incubating in 17 mM DTT for 1 hour at 56°C 
and then alkylated with 0.1M iodoacetamide for 1 hour at room temperature in the dark. 
The protein was precipitated with 10% TCA at 4°C for 10 minutes then spun down at 
14,000 rpm for 2 minutes. The precipitated pellet was washed by bath sonication in 95% 
ethanol three times. After the last wash all the ethanol was removed and resuspended in a 
CNBr solution. The CNBr solution contained 500 molar excess of CNBr per methionine 
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in the sample in approximately 80% TFA. The samples were then kept in the dark for 24 
hours with the sonicator on for approximately 12 hours. After CNBr digestion, the 
samples were dried as much as possible in the hood with a stream of argon. Then a hole 
was punched in the top of the eppendorf tube, wrapped in parafilm and put into speedvac. 
Once dry, the pellet was then suspended in 100 µL of ddH2O, sonicated, and dried on a 
speedvac. The samples were then digested further with trypsin by the Proteomics Facility 
at Rockefeller University or by following the protocol adapted from the Proteomics 
facility. In brief, the dried samples from the CNBr digestion were then dissolved in 20 µL 
of 6M urea in 200 mM ammonium bicarbonate. Samples were then reduced and alkylated 
again as described above. Then ammonium bicarbonate buffer was added to both samples 
to reduce the urea concentration to below 1 M. Trypsin Gold (Promega) was then added 
to the samples for a final concentration of 0.2 µg of trypsin per 1 µg of sample protein. 
The samples were then kept at 37°C for 36 hours on a shaker. Following digestion, 
formic acid was added to the samples so that the final concentration of formic acid was 
10% to terminate the trypsin reaction. The digested sample then either went through a 
second purification as described below or was submitted to the Proteomics Facility at 
Rockefeller University for LC-MS/MS analysis. 
 
2.10.2. Immunopurification with anti-Fluorescein (anti-FL) Antibody.  
HEK293T cells heterologously expressing WT CCR5 were crosslinked to a fluorescein 
labeled analogue of maraviroc containing benzophenone (FL-MVC-bp) as described 
above. After crosslinking the cell pellets were solubilized in 1% DM in 20 mM Tris pH 
7.5 containing protease inhibitors for 1 hour at 4°C on a nutator. The lysate was then 
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spun down and the supernatant was bound to protein A dynabeads (Invitrogen) that were 
pre-bound to a rabbit polyclonal anti-fluorescein antibody (abcam #ab19491) as 
described by the manufacturer. The samples incubated with the beads overnight at 4°C. 
The next day the unbound fraction was removed and the beads were washed 3 times with 
the 1% DM buffer. The samples were then eluted either in 50 mM glycine pH 2.5 for 1 
hour at room temperature if being submitted for mass spectrometry analysis or eluted in 
1X NuPAGE LDS sample buffer containing DTT for 1 hour at 37°C for Western Blot 
analysis. 
 
2.10.3. Liquid Chromatography – Tandem Mass Spectrometry (LC-MS/MS) Analysis 
of Digested Protein Samples.  
Protein samples were digested as described above and submitted to the Proteomics 
Resource Center at Rockefeller University for LC-MS/MS analysis. Prior to the analysis, 
the samples were cleaned up with C18 Stage (stop-and-go-extraction) Tips. The tips were 
first washed with 70% acetonitrile containing 2% formic acid and then conditioned with 
2% formic acid in HPLC-grade water. The samples were loaded onto the tips, washed 
with 2% formic acid in water, and eluted using 70% acetonitrile and 2% formic acid 
mixture. Samples were subsequently dried using a speed vac and resuspended in 5% 
acetonitrile and 2% formic acid mixture. One third of each sample was loaded onto a C18 
PepMap1000 micro-precolumn (300 µm I.D., 5 mm length, 5 µm beads Thermo 
Scientific) at a flow-rate of 5 µL/min., and then injected onto an analytical C18 column 
(75 µm I.D., 3 µm beads, Nikkyo Technos Co.) at a flow rate of 300 nL/min. The 
gradient was 125 minutes long in the range of 5-45% B (buffer A was 0.1% formic acid 
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in water, and buffer B was 0.1% formic acid in acetonitrile.) Eluted peptides were 
electrosprayed directly into the LTQ-Orbitrap XL mass spectrometer from Thermo 
Scientific, that operates in a 300-1800 m/z mass range. Tandem mass spectrometry was 
performed by collision-induced dissociation using nitrogen as a collision gas. The 
resulting spectra were then analyzed using Proteome Discoverer software (Thermo 
Scientific) to identify the peptides in the sample. 
 
2.11. Imaging of Fluorescent-SDF-1α Binding to Cells.  
 
(Performed with Dr. Joelle Goulding at the University of Nottingham in Dr. Stephen 
Hill’s Lab) HEK GloSensor cells (Promega) stably expressing a CXCR4 construct 
containing a SNAP-tag at the N-terminus (Cisbio) were grown on 8-chamber coverslips. 
Prior to imaging, the cells were labeled with the SNAP-substrate 488 at 0.5 µM for 1 
hour at room temperature and were then washed with 1X HBSS containing 2% BSA. 
After labeling the cells were incubated with 10 nM SDF-1α-RED (Cisbio) in 1X HBSS 
with 2% BSA for 10 minutes at 37°C in the presence or absence of a 30-minute pre-
incubation with 100 nM SDF-1α or 10 µM AMD3100. The cells were then imaged on a 
Zeiss LSM 710 laser scanning confocal microscope with an argon 488 laser with a band 
pass 493-603 filter for the SNAP label and a Helium Neon 633 laser with a band pass 










Figure 2-8. Imaging of fluorescent-SDF-1α binding to cells. This figure shows that we 
were able to detect specific binding of SDF-1α-RED to live cells expressing CXCR4. 
Minimal background was detected to untransfected cells. In addition, the binding of SDF-
1α-RED to CXCR4 expressing cells was shown to be specific as it could be competed off 
with unlabeled SDF-1α and AMD3100, a CXCR4-specific inhibitor. 
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CHAPTER 3: Results 
 
3.1. Investigating Ligand Binding Sites on CXCR4 
 
3.1.1. Photocrosslinking Studies of the CXCR4-T140 complex.  
Adapted with permission from (Grunbeck, A., et al. (2011) Biochemistry 50, 3411-3413). 
Copyright (2011) American Chemical Society. 
 
We used the CXCR4-T140 complex to validate the targeted photocrosslinking 
technology for identifying GPCR-ligand binding interfaces. The site-directed 
crosslinking technology relies on a specific and sensitive detection method to identify 
both binding partners in the crosslinked complex.  We accomplish this by attaching a 
unique antibody reactive tag on each complex component. CXCR4 contains a C-terminal 
C9 epitope tag for mAb 1D4, and T140 is labeled with fluorescein (Figure 3-1A).  The 
fluorescein tag is used for specific detection by immunoblot analysis using an anti-
fluorescein antibody. Fluorescein was directly conjugated to Lys 8 on T140, which does 
not interfere with binding to CXCR4 105,106.  Thus, fluorescein-T140 (FL-T140) is a 
suitable ligand to validate the application of the site-directed crosslinking technology. 
First, to optimize conditions for crosslinking and detection of the FL-
T140/CXCR4 complex, we used a T140 analogue containing fluorescein and BzF at 
position 10 (FL-T140-BzF).  This T140 derivative has been reported to crosslink to 








Figure 3-1. FL-T140-BzF crosslinks specifically to CXCR4. (A) Chemical structure of 
FL-T140. (B) Western blot analysis of FL-T140-BzF crosslinked to HEK293T cells 
transfected with CXCR4. Cells were solubilized in detergent and the lysate was 
immunopurified with Sepharose beads conjugated to the 1D4 antibody. Samples were 
eluted from the beads and loaded onto two SDS-PAGE gels that were transferred and 
blotted with either the monoclonal 1D4 antibody or anti-fluorescein polyclonal antibody. 
The UV-dependent anti-fluorescein band at the molecular mass of CXCR4 indicates FL-
T140-BzF is crosslinked to CXCR4. (C)This crosslink is shown to be specific as no 
crosslink is detected when 100-fold excess of unlabeled T140 is present. In addition, no 
crosslink is detected to HEK293T cells transfected with CCR5 or in mock-transfected 
cells. Adapted with permission from (Grunbeck, A., et al. (2011) Biochemistry 50, 3411-




  	  
crosslinks specifically to CXCR4 in cell culture.  CXCR4-transfected HEK293T cells 
were incubated with FL-T140-BzF prior to UV light exposure. Following UV exposure, 
the cells were solubilized in detergent and CXCR4 was immunopurified from the lysate 
using sepharose beads conjugated to the 1D4 mAb.  An immunoblot of the purified 
samples showed a UV-treatment-dependent band on the anti-fluorescein blot at the 
molecular mass of the receptor (Figure 3-1B & C). This indicates the existence of a 
covalent complex between FL-T140-BzF and CXCR4, which was not detected if a 100-
fold excess of unlabeled T140 was present. Additionally, no crosslink was detected in 
untransfected cells or to CCR5, another chemokine receptor with high homology to 
CXCR4, demonstrating the specificity of T140 for CXCR4. The fluorescein moiety also 
proved to be a specific and sensitive detection tag on an immunoblot using an anti-
fluorescein polyclonal antibody. 
For the site-specific crosslinking experiments from the side of the receptor, 
residues in CXCR4 were chosen for replacement with a photocrosslinking UAA based on 
previously reported biochemical and molecular modeling data. The CXCR4 schematic 
shows the sites, which when mutated to an Ala, caused a decrease in T140 inhibition of 
HIV-1 entry (Figure 3-2A) 108.  Although in principle any amino acid residue can be 
targeted for amber codon suppression, we chose Phe residues in close proximity to these 
sites for replacement with BzF or azF in order to make mutations that would be the least 
likely to perturb the native structure of the receptor. These UAAs were incorporated one-
by-one at each position using an engineered BzF or azF amino-acyl tRNA synthetase and 
suppressor tRNA pair that recognize an amber stop codon (UAG) on the receptor mRNA 
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95. Incorporation of BzF at the position of the amber stop codon in CXCR4 was 
confirmed by immunoblot to detect full-length receptor (Figure 3-2B).  
Introducing UAAs into GPCRs alters the native sequence of the receptor, but the 
proper folding and function of the receptor can be retained, as has been reported for the 
incorporation of UAAs into other GPCRs, including rhodopsin and CCR5 95,97,109. For 
this experiment, we determined whether incorporation of BzF into CXCR4 affects 
binding to T140 by examining the crosslinking efficiency of FL-T140-BzF to each of the 
CXCR4 BzF-containing mutants. All of the mutants crosslinked to FL-T140-BzF, 
indicating that T140 is able to bind to the CXCR4 variants containing BzF (Figure 3-2C). 
Each of the CXCR4 BzF mutants were then tested for UV-induced crosslinking to FL-
T140. HEK293T cells expressing the CXCR4 BzF mutants were incubated with FL-T140 
and then exposed to UV light. The cells were then scraped and solubilized in detergent 
and the lysate was separated on a SDS-PAGE gel and subjected to immunoblot analysis. 
The results from this series of experiments showed an anti-fluorescein positive 
band at the molecular mass of CXCR4 only when BzF was introduced at position 189 
(Figure 3-3A) or when BzF was at position 10 in FL-T140-BzF (Figure 3-3B). The same 
crosslinking experiment was also performed in the presence of 100-fold excess of 
unlabeled T140. In this case no band was detected with the anti-fluorescein antibody, 
which demonstrates the specificity of the crosslink at position 189 for T140 (Figure 3-
3C). The same results were also seen with azF at the same sites in CXCR4, although 
background crosslinking without UV treatment was significantly higher when using azF 
as compared to BzF (Figure 3-3D).  
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Figure 3-2. Expression analysis and ligand binding evaluation of CXCR4 UAA mutants. 
(A) CXCR4 schematic highlighting sites important for T140 binding (green) as 
determined by alanine scanning 108 and positions where a UAA was incorporated 
(orange). (B) CXCR4 amber mutants were co-expressed in HEK293T cells with a 
suppressor tRNA and BzF amino-acyl tRNA synthetase pair. Growth media either 
contained or did not contain 0.5 mM BzF. Full-length receptor was detected on a western 
blot using the 1D4 mAb, which recognizes an epitope on the C-terminus of the receptor. 
1D4-positive bands are only present when BzF was added to the growth medium 
indicating that BzF is being incorporated at the position indicated. Similar results were 
obtained for F174amb and F189amb. (C) HEK293T cells expressing each of the CXCR4 
BzF mutants were incubated with 100 nM FL-T140-BzF. After incubation cells were 
exposed to UV light for 15 minutes, solubilized in detergent, lysate separated by SDS-
PAGE, and evaluated by western blot analysis. All CXCR4 BzF containing mutants were 
shown to crosslink to FL-T140-BzF. This indicates that incorporation of BzF at these 
positions does not affect binding to T140. Therefore in the crosslinking experiments 
shown in Figure 3-3, the data show that under the crosslinking conditions the ligand is 
bound to the CXCR4 UAA mutant.  It follows therefore that the absence of a crosslink is 
most likely due to the reactive free radical being too far away from any potentially 
reactive group on the bound ligand. Adapted with permission from (Grunbeck, A., et al. 
(2011) Biochemistry 50, 3411-3413). Copyright (2011) American Chemical Society. 
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Figure 3-3. Photocrosslinking of CXCR4 UAA mutants to FL-T140. (A) Western blot 
analysis of lysate from HEK293T cells expressing CXCR4 BzF mutants that were 
exposed to UV light in presence of FL-T140. CXCR4 189BzF was the only CXCR4 BzF 
mutant that crosslinked to FL-T140. (B) As a positive control FL-T140-BzF was 
crosslinked to WT CXCR4. Background crosslinking was not detected between WT 
CXCR4 and FL-T140. (C) Crosslinking of CXCR4 189BzF to FL-T140 was performed 
in the absence and presence of a 100-fold excess of unlabeled T140. The band on the 
anti-fluorescein blot disappeared in the presence of excess T140. (D) Crosslinking results 
for CXCR4 189azF to FL-T140.  Crosslink was specific for position 189, but background 
crosslinking, most likely due to exposure to ambient room light, was detected.  
Background was not detected when BzF was used as the photocrosslinker. Adapted with 
permission from (Grunbeck, A., et al. (2011) Biochemistry 50, 3411-3413). Copyright 
(2011) American Chemical Society. 
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3.1.2. Investigating the binding interaction between a pepducin and CXCR4 
 
We investigated the binding site of the CXCR4-specific pepducin, ATI-2341, by 
performing a competition study to determine if this ligand has an overlapping binding site 
with T140 on CXCR4. HEK293T cells heterologously expressing CXCR4 were co-
incubated with FL-T140-BzF and a 100-fold excess of another ligand, which included 
AMD3100, a CXCR4-specific small molecule inhibitor, ATI-2341, and maraviroc, a 
CCR5-specific small molecule inhibitor. After a 10 minute incubation at 37°C the cells 
were then exposed to UV light for 15 minutes. The cell lysates were then run on a SDS-
PAGE gel and detected by Western Blot analysis. The blot detected with anti-fluorescein 
shows a disappearance of the fluorescein band at the molecular weight of CXCR4 when 
the cells weren’t exposed to UV light or were co-incubated with unlabeled T140. A slight 
decrease is seen in the band on the anti-fluorescein blot when AMD3100 is present, but 
no change is observed with the presence of ATI-2341 or maraviroc (Figure 3-4) 31. This 
suggests that ATI-2341 is unable to compete with T140 for binding to CXCR4. 
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Figure	   3-­‐4. Competition of CXCR4 ligands with T140 binding. T140 binding to 
HEK293T cells expressing WT CXCR4 is detected using a T140 analogue labeled with 
fluorescein (FL) and containing p-benzoyl-L-phenylalanine (BzF), a photoactivatable 
crosslinker. A UV-dependent crosslink between FL-T140-BzF and CXCR4 is detected on 
a Western Blot using a polyclonal anti-fluorescein antibody. This band disappears when 
the experiment is performed in the presence of 100-fold excess of unlabeled T140, which 
indicates that the crosslink is specific for T140. There is a slight decrease in the amount 
of FL-T140-BzF crosslinked to CXCR4 when AMD3100, a CXCR4-specific small 
molecule inhibitor is present, although as can be seen on the Western Blot detected with 
the 1D4 antibody this sample had a slightly lower amount of CXCR4 present. This 
difference in receptor expression, which we believe is due to the protein amounts in the 
samples not being normalized, might be the reason for the detection of a decrease in FL-
T140-BzF crosslinking. The band on the anti-FL Western Blot does not change if the 
experiment is performed in the presence of 100-fold excess of ATI-2341, or maraviroc, a 
CCR5-specific inhibitor. These results show that none of these ligands compete with 
T140 for binding to CXCR4 and therefore do not have overlapping binding sites. 
Adapted from (Janz, J., Ren, Y., Looby, R., Kazmi, M., Sachdev, P., Grunbeck, A., et al. 




  	  
 Additionally, since ATI-2341 mimics the i1 loop of CXCR4 we were interested 
in determining the relevance of this peptide sequence to the function of CXCR4. We 
mutated the residues in CXCR4, Met 63 through Leu 78, that corresponded to the 
sequence of ATI-2341 to the homologous sequence in CCR5. We reference the 
CXCR4/CCR5 chimeric receptor as CXCR4_R5i1. CCR5 has high homology to CXCR4, 
but ATI-2341 does not bind or activate this receptor. Therefore we can use CXCR4_R5i1 
to see if the native i1 loop in CXCR4 is necessary for pepducin activity. This could 
indicate whether the pepducin is mimicking the active state of the receptor or if it is 
acting as an allosteric modulator to stimulate an active conformation of the receptor. In 
the first step of this project, we created the CXCR4_R5i1 construct and tested for cell 
surface expression of the receptor using a cell-based ELISA. HEK293T cells were 
transfected with the construct and plated into a 96-well plate. A conformationally 
sensitive antibody that recognizes an epitope on the extracellular surface of the receptor 
was used to detect correctly folded receptor at the plasma membrane under 
paraformaldehyde (PFA) treatment of the cells. The conformationally sensitive antibody 
for CXCR4 is 12G5 and 2D7 is specific for CCR5. Total receptor expression was 
determined by fixing the cells with methanol, which allows the antibody to permeate the 
membrane. The 1D4 antibody was used to measure total receptor expression by 
recognizing a linear epitope at the C-terminus of the receptors. Non-specific binding of 
the secondary antibody was determined by measuring binding of the secondary antibody 
to fixed cells without primary antibody present. The cell surface ELISA results show that 
relatively the same amount of WT CXCR4 and CXCR4_R5i1 was detected with the 
12G5 antibody. All three receptors had relatively the same signal with the 1D4 antibody. 
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Also, the levels of primary antibody binding to transfected cells was significantly above 
what was detected for untransfected cells, which suggests that antibody binding is 
specific (Figure 3-5). These findings suggest that replacement of the i1 loop in CXCR4 
does not affect expression of the receptor or translocation of the receptor to the plasma 
membrane. Further characterization of the CXCR4_R5i1 will be carried out by the Hill 
Lab at the University of Nottingham as discussed later in this manuscript. 
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Figure 3-5. Cell surface expression of CXCR4-R5i1. A cell-based ELISA was used to 
measure cell surface expression of the CXCR4-CCR5 chimera CXCR4-R5i1. 
Untransfected HEK293T cells and cells transfected with WT CXCR4, CXCR4_R5i1, or 
WT CCR5 were plated into a 96-well plate. Cells were fixed with PFA for treatment with 
either 2D7 or 12G5, which recognize a conformational epitope on the extracellular 
surface of the receptor. MeOH fixation was used with the 1D4 antibody, which 
recognizes an epitope on the cytoplasmic side of the receptor. Non-specific binding of the 
secondary antibody was measured in the absence of primary antibody. The data shows 
similar levels of specific 1D4 and 12G5 binding for both WT CXCR4 and CXCR4_R5i1. 
CCR5 also showed a comparable 1D4 signal. Primary antibody binding to transfected 
cells was also significantly above that seen for untransfected cells indicating that 
antibody binding is specific. The lack of signal when no primary antibody is present also 




  	  
3.2. Photocrosslinking Study of CCR5-Maraviroc Complex.  
Adapted with permission from (Grunbeck, A., et al. (2012) ACS Chem. Biol. 7, 967-972). 
Copyright (2012) American Chemical Society. 
 
We applied the targeted photocrosslinking technique to investigate the binding 
site of the small molecule HIV-1 inhibitor, maraviroc, on its target receptor CCR5 
(Figure 3-6a). For this study we used a tritiated version of maraviroc in order to retain the 
native structure of the small molecule.  We chose positions in CCR5 to replace with BzF 
or azF, based on earlier models of the maraviroc-binding site, with the expectation that a 
loss-of-function phenotype would not be observed.  These earlier studies proposed 
models of the maraviroc binding-site in CCR5 based on scanning mutagenesis, molecular 
dynamics simulations, or structure-activity relationship studies110-112. Some of this work 
was based on studies of other structurally related CCR5 pharmacophores such as TAK-
779113,114. From this earlier data, we chose 8 positions in CCR5 for additional study 
(Figure 3-6b). Our aim was to create a set of CCR5 UAA mutant receptors that would 
bind maraviroc normally and in addition contain reactive side chains that might crosslink 















Figure 3-6. Targeted photocrosslinking was employed to study the binding site of 
maraviroc on CCR5. (A) Chemical structure of the CCR5-specific HIV-1 entry inhibitor 
maraviroc. (B) A schematic of the CCR5 structure showing in blue the positions in the 
receptor where BzF and azF were introduced. Adapted with permission from (Grunbeck, 





  	  
 
3.2.1. Functional Characterization of CCR5 UAA mutants 
 
3.2.1.a. [3H]-maraviroc binding  
 
To evaluate whether the CCR5 UAA mutants retain binding to maraviroc we 
performed ligand-binding experiments with [3H]-maraviroc. These experiments were 
performed in parallel with the photocrosslinking studies. After cells expressing the CCR5 
UAA mutants were incubated with [3H]-maraviroc, exposed to UV light, lysed in 
detergent, and receptors were immunopurified, a portion of the eluted samples were put 
into vials with scintillation fluid and counted on a beta-scintillation counter. The amount 
of tritium detected in each of the samples was then plotted on a bar graph (Figure 3-7).  
All of the CCR5 UAA mutants show relatively the same amount of [3H]-maraviroc 
binding when both BzF and azF is incorporated at the position indicated, except for 
residue Trp 86. The CCR5 W86BzF mutant shows significantly decreased levels of 
binding to maraviroc as compared to CCR5 W86azF. Most of the CCR5 UAA mutants 
retain about 50% of binding to maraviroc as compared to WT. It is important to note that 
these differences could be a result of a difference in receptor expression level in addition 
to a change in ligand binding affinity.  The relative expression levels of the CCR5 BzF 
and azF mutants are depicted in the Western Blot shown in Figure 3-9. The Western Blot 
shows total receptor expression in the cell lysate as detected with the 1D4 antibody. As 
can be seen in this figure the expression levels vary significantly between different 
mutants, such as between CCR5 Y108BzF and CCR5 F109BzF. The [3H]-maraviroc 
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binding data appears to correlate with the relative expression level differences seen on the 
Western Blot, although the Western Blot does not give any information about the amount 
of correctly folded or functional receptor that is expressed in the cell. We expect that the 
population of receptors expressed in the cell is heterogeneous and it is unknown what 
percentage of these overexpressed proteins is actually folded correctly. This is another 
factor that could play into the differences in the amount of [3H]-maraviroc that is able to 
bind each CCR5 UAA mutant. 
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Figure 3-7. [3H]-maraviroc binding. CCR5 UAA mutants retain binding to maraviroc. 
Each of the CCR5 UAA mutants was measured for their ability to bind maraviroc under 
the conditions of the crosslinking experiments. In brief, after the HEK293T cells 
expressing the CCR5 UAA mutants were incubated with [3H]-maraviroc, exposed to UV 
light and then solubilized in detergent, the receptors were then immunopurified from the 
lysate using sepharose beads conjugated to the 1D4 mAb. The beads were then washed, 
samples were eluted using SDS, and the amount of tritium in the elution was quantified. 
The [3H]-maraviroc detected in the elution was determined to be a result of being 
specifically bound to the purified receptor.  This was supported by no tritium was 
detected in the sample with the homologous receptor, CXCR4, which is unable to bind 
maraviroc. Therefore the amount of tritium in the eluted samples was quantified for each 
CCR5 UAA mutant to determine the amount of [3H]-maraviroc that was specifically 
bound. The values were then normalized to each other by setting the amount of tritium 
that was bound to WT CCR5 as an equivalent to 100% binding. The error bars are a 
result of averaging the values obtained from the sample that was exposed to UV light 
with the sample that was not. The differences in binding between the mutants are a result 
of varied expression levels of each of the mutants and differences in binding affinity for 
maraviroc. This graph shows that all of the mutants retain significant binding to 
maraviroc except for the CCR5 W86BzF mutant. Adapted with permission from 




  	  
 
3.2.1.b. Calcium Flux assay  
 
Another method to evaluate whether CCR5 UAA mutants retain their native structure and 
function is through live cell-based calcium flux assays. This is a high-throughput assay 
where cells are loaded with a calcium-dependent fluorescent dye. The change in 
cytoplasmic calcium levels is measured in response to treatment of cells with the 
chemokine RANTES. A RANTES dose-response curve is then plotted versus the change 
in fluorescence that was recorded upon addition of the ligand. We can then use these 
plots to calculate the RANTES EC50.  This was carried out for a few CCR5 BzF mutants 
(Table 3-1). These mutants were found to have RANTES EC50 values that are 
comparable to WT CCR5, which suggests that replacing F85, Y108, or F109 in CCR5 
with BzF does not significantly alter the receptor’s function or RANTES binding 
capabilities.  
 






  	  
 
3.2.2. Photocrosslinking CCR5 UAA Mutants to [3H]-maraviroc.  
 
We expressed each of the selected CCR5 amber mutants in HEK293T cells under 
conditions designed to incorporate either BzF or azF at the position of interest. Cells 
expressing the CCR5 UAA mutants were incubated with [3H]-maraviroc and then 
exposed to UV light. Cells were lysed in detergent buffer solution and receptors were 
immunopurified using 1D4 mAb. The immunopurified material was then run on an SDS-
PAGE gel to separate out any tritiated ligand that was not covalently bound to the 
receptor. After transferring proteins to a PVDF membrane and measuring receptor 
expression by immunoblot analysis, the PVDF membrane was then cut into strips to 
partition each sample. Each sample strip was cut further into segments and the amount of 
radioactivity in each segment was measured (Figure 3-8). 
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Figure	  3-­‐8. Experimental scheme for the targeted photocrosslinking technology using a 
radiolabeled ligand.  The first step involves incubating HEK293T cells expressing the 
CCR5 UAA mutants with [3H]-maraviroc. After incubation the cells were exposed to 
365-nm UV light in a 24-well plate format. The cells were then lysed in detergent buffer 
solution and receptors were immunopurified, run on an SDS-PAGE gel, transferred to a 
PVDF membrane, and immunoblotted to determine receptor expression. The sample 
lanes were then cut from the PVDF membrane and each sample lane was cut into three 
different molecular weight segments. These membrane segments were then put into 
scintillation vials with scintillation fluid and then counted on a beta-scintillation counter 
to quantify the amount of radioactivity in each segment. Adapted with permission from 




  	  
 
These experiments showed that 3 of the 8 positions in CCR5 engineered to 
contain either azF or BzF were able to form a covalent bond with [3H]-maraviroc upon 
UV illumination (Figure 3-9).  Among the positions tested, different patterns of reactivity 
were noted for CCR5 containing azF versus BzF.  Significant tritium was detected in the 
CCR5-maraviroc complex when either Ile 28 or Trp 86 was replaced by azF.  However, 
when BzF was incorporated at position Ile 28, only a slight increase above background 
was detected. A significant increase in tritium levels was detected, however, when BzF 
was incorporated at position Phe 109, a site that did not crosslink when azF was present.   
For these 4 mutants (CCR5 I28azF; CCR5 W86azF; CCR5 I28BzF; CCR5 
F109BzF) the elevated levels of tritium were detected only in the 25-50 kDa gel fraction, 
which includes CCR5 with an apparent molecular mass of approximately 37 kDa. Since 
the molecular mass of maraviroc is under 500 Da, tritium only appears in the 25-50 kDa 
fraction if the [3H]-maraviroc is covalently bound to CCR5. These crosslinking results 
were also found to be UV-treatment-specific (Figure 3-10). 
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Figure 3-9. Photocrosslinking results with CCR5 azF and BzF replacement mutants. (A) 
CCR5 azF mutants were tested for crosslinking to [3H]-maraviroc. Receptor expression is 
shown by immunoblot analysis with the 1D4 antibody.  Note that the exposure for each 
sample is not normalized across all lanes. Each lane corresponds to the mutant shown in 
the bar graph directly below. The colors highlighted on the Western Blot designate where 
the membrane was cut for scintillation counting and correlate with the colors in the bar 
graph.  The bar graph reports the amount of tritium detected in the PVDF segments 
indicated.  All of these samples represent the CCR5 azF mutants that were exposed to UV 
light in the presence of [3H]-maraviroc. The membrane segment of interest is the 25-50 
kDa segment (red), which contains CCR5.  The CCR5 band is indicated with the arrow at 
37 kDa. The other strong band at 25 kDa is the light chain from the 1D4 mAb, which was 
used for immunopurification.  Positions 28 and 86 were the only two sites found to have 
significantly higher tritium levels in the 25-50 kDa segment. (B) The same positions in 
CCR5 were also tested for crosslinking using BzF.  This data set is displayed as in panel 
a. Positions 28 and 109 were found in this crosslinking scan to have significantly higher 
tritium levels in the 25-50 kDa segment. Adapted with permission from (Grunbeck, A., et 








Figure 3-10. Photocrosslinking results with CCR5 UAA mutants. The data set is from 
the same experiment that is shown in Figure 3-9, except here we include the control 
sample for each mutant that was not exposed to UV light.  The three bar graphs shown 
here display the amount of tritium detected in the 50 – 100 kDa segment (top), 25 – 50 
kDa segment (middle), and 15 – 25 kDa segment (bottom). Panel (A) is the data for azF 
and shows that the elevated levels of tritium detected in the 25 – 50 kDa segment for the 
I28azF and W86azF mutants is UV-specific. Panel (B) displays the data when BzF is 
introduced into CCR5. This data shows that the elevated levels of tritium detected in the 
25 – 50 kDa segment for the I28BzF and F109BzF mutants is UV-specific. These results 
support the conclusion that the increases in tritium levels at the molecular weight of the 
receptor are a result of a covalent crosslink between the UAA at the positions specified in 
CCR5 and [3H]-maraviroc. Adapted with permission from (Grunbeck, A., et al. (2012) 




  	  
3.2.3. Digestion of CCR5 and MS analysis  
 
The targeted photocrosslinking technique enables the identification of the exact 
position in the receptor that is involved in the formation of the covalent crosslink with the 
ligand. To identify the site of the crosslink in maraviroc we optimized a chemical and 
enzymatic digestion strategy to detect peptide fragments of CCR5 by mass spectrometry. 
CCR5 was expressed in HEK293T cells, lysed in a detergent containing buffer and 
immunopurified with the 1D4 mAb. The purified receptor was reduced and alkylated and 
then precipitated with TCA. The receptor was digested with cyanogen bromide (CNBr) 
and trypsin and then analyzed by LC-MS/MS by the Proteomics Facility at Rockefeller 
University. The CCR5 peptides detected resulted in approximately 50% sequence 
coverage. Most of these peptides were identified by performing a non-specific search, 
which indicates that the receptor was not digested at locations predicted for CNBr and 
trypsin digestion. CNBr hydrolyzes peptide bonds at the carboxyl side of Met residues 
and trypsin cleaves peptide bonds at the carboxyl end of Arg and Lys. Some of the 
peptides identified seemed to be more likely digested by chymotrypsin, which cleaves 
peptide bonds at the C-terminal side of Phe, Tyr, and Trp. This is not entirely uncommon 
as most trypsin samples are reported to have some level of chymotrypsin activity. 
Although these peptides were not identified when the sample was only digested with 
chymotrypsin, which might suggest that the concentration of enzyme used could be 
important to obtain particular digestion patterns or the digestion of CCR5 is not very 
reproducible. Further experiments need to be performed to obtain a very robust and 
reproducible digestion protocol for CCR5. The peptides listed in Table 3-2 were detected 
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in two separate trypsin digestions of the same CNBr-treated sample. The peptide of 
interest is highlighted in red as this peptide contains Phe 109, which is a position that had 
high crosslinking efficiency with [3H]-maraviroc.   
 
Table 3-2. The peptide fragments detected by LC-MS/MS after digestion of CCR5 with 
CNBr and trypsin. 
 
 
3.2.4. Fluorescein as a Purification Handle  
 
An additional CCR5-maraviroc photocrosslinking study was performed using a 
fluorescein-labeled maraviroc analogue (FL-maraviroc). A version of this ligand was also 
synthetized to contain a benzophenone group (FL-MVC-bp). Dr. Martin Teintze from 
Montana State University provided both of these maraviroc analogues. A panel of CCR5 
BzF containing mutants was examined for crosslinking to FL-maraviroc as described for 
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the CXCR4-FL-T140 crosslinking experiments. HEK293T cells expressing each of these 
mutants were exposed to UV light in the presence of FL-maraviroc. After solubilization 
of the cells, the receptors were immunopurified and run on an SDS-PAGE gel. The 
crosslinks were then detected by Western Blot analysis using an antibody that reacts with 
fluorescein. The results from this experiment identified two bands on the anti-fluorescein 
blot at the molecular weight of CCR5, which were present when BzF was introduced at 
position Ile 23 and Phe 109 (Figure 3-11). These bands were not detected when 100-fold 
excess of maraviroc was present during the crosslinking experiment. Since FL-maraviroc 
has a molecular weight of less than 1 kDa, detection of a fluorescein positive band at 37 
kDa on a denaturing gel indicates that the ligand is covalently bound to the receptor. 
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Figure 3-11. Photocrosslinking of CCR5 BzF mutants to FL-maraviroc. (A) The 
structure of the fluorescein-maraviroc (FL-maraviroc) analogue. (B) The CCR5 BzF 
mutants were examined for their crosslinking potential to FL-maraviroc. Receptor 
expression is probed on a Western Blot using the 1D4 antibody, which recognizes an 
epitope at the C-terminus of the receptor. Two sites (Ile 23 and Phe 109) were found to 
crosslink specifically to FL-maraviroc as shown by the bands on the anti-fluorescein 




  	  
 
Another advantage of using a fluorescein-labeled ligand in this context is the 
fluorescein moiety has the potential to be used as a purification tag. This is particularly 
beneficial for preparing samples for mass spectrometry analysis where the fluorescein-
containing peptides can be purified post-digestion of the crosslinked receptor-ligand 
complex. We tested the ability of the anti-fluorescein antibody to purify two receptor-
ligand crosslinked complexes, CXCR4-(FL-T140-BzF) and CCR5-(FL-MVC-bp). For 
the immunopurification step the anti-fluorescein antibody was pre-bound to protein G 
magnetic Dynabeads. Cells expressing CXCR4 or CCR5 were exposed to UV light in the 
presence or absence of the cognate ligand containing a fluorescein and benzophenone 
group. The cell lysates were bound to the anti-fluorescein beads overnight at 4°C and 
then samples were eluted and run on a SDS-PAGE gel. The presence of receptor and 
ligand were then detected via Western Blot analysis. The 1D4 immunoblot shows bands 
corresponding to CXCR4 (~40kDa) and CCR5 (~37 kDa) only when the fluorescein-
labeled ligand was present (Figure 3-12). These bands are also shown to contain 
fluorescein as is seen by the bands on the anti-fluorescein immunoblot. The bands 
detected on both blots above 50 kDa are either antibody that eluted from the beads or 
receptor aggregates. These results suggest that the anti-fluorescein beads are able to 
specifically purify the crosslinked receptor-(FL-ligand) complex. 
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Figure 3-12. Immunopurification with anti-fluorescein (anti-FL) antibody. HEK293T 
cells expressing CXCR4 or CCR5 were exposed to UV-light in the absence or presence 
of FL-T140-BzF or FL-MVC-bp as indicated. Cells were solubilized in detergent and the 
lysate was incubated with Dynabead pre-bound to the anti-FL antibody. Samples were 
eluted from the beads and run on an SDS-PAGE gel and immunoblotted. The bands on 
the 1D4 immunoblot are only present in the lanes that contained the FL-labeled ligand. In 
addition, these bands are also shown to be anti-FL positive. This indicates that the 




  	  
CHAPTER 4: Discussion 
 
4.1. Ligand Binding Sites on CXCR4 
 
4.1.1. Binding interaction with the cyclic-peptide inhibitor T140.  
Adapted with permission from (Grunbeck, A., et al. (2011) Biochemistry 50, 3411-3413). 
Copyright (2011) American Chemical Society. 
 
The CXCR4-T140 complex proved to be an ideal model system to validate the 
targeted photocrosslinking strategy. Previously, CXCR4-T140 complex models were 
developed using mutagenesis and crosslinking techniques, which included chemical- and 
photocrosslinking using a T140 analogue containing BzF. These strategies required 
digestion of CXCR4 to determine the site in the receptor that was covalently bound to the 
T140 analogue 108,115. These experiments were only able to resolve a peptide fragment of 
CXCR4 that was bound to T140.  CXCR4-T140 complex models derived from these 
studies differ from the crystal structure of CXCR4 bound to CVX15, a 16-residue peptide 
with high homology to T140 23. The difference between the CXCR4-T140 complex 
models and the crystal structure of the CXCR4-CVX15 complex result from the inability 
of earlier crosslinking techniques to identify the exact site in CXCR4 that crosslinked 
with T140. We were able to identify the precise site of crosslinking between CXCR4 and 
T140 by introducing BzF at a specific position in CXCR4 expressed in cells using amber 
codon suppression. Out of the 8 sites in CXCR4 that were tested, position 189 was the 
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only location found to form a UV-dependent covalent crosslink with FL-T140. This 
crosslink was detected when Phe 189 was replaced with both BzF and azF, although the 
presence of a UV-independent crosslink with azF might suggest activation of this 
molecule by ambient room light. These results suggest that Phe 189 in CXCR4 is within 
close proximity to the T140 binding site, whereas the other CXCR4 residues examined 
are not. 
These findings were evaluated in the context of the crystal structure of CXCR4 
bound to CVX15, a 16-residue peptide with high homology to T140, to verify the 
application of this technology to identify residues in CXCR4 that are within close 
proximity to the T140 binding site. Assuming that T140 has a similar binding site as 
CVX15, Phe 189 immediately stands out from the other sites as being within crosslinking 
distance to the ligand (Figure 4-1A&B). Since the crystal structure is limited to a single 
static image, Dr. Huber carried out computational modeling to predict the possible 
orientations of BzF at each of these sites (Figure 4-1C). He calculated the distance 
between the center-of-mass of the reactive carbonyl in BzF to the nearest atom in the 
CVX15 peptide for each of the possible orientations of BzF at each position. BzF at 
position 189 was the only site to have a reasonably high probability of being within 2 to 5 
Å from the peptide – all other potential carbonyl-CVX15 atom pairs were greater than 5 
Å apart (Figure 4-1D).  
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Figure 4-1. Molecular modeling of CXCR4 BzF mutants. (A) Crystal structure of 
CXCR4 bound to CVX15 (cyan) with residues replaced with UAAs highlighted in orange 
23. N-terminus of receptor is highlighted in blue and fades to red at the C-terminus. (B) A 
90o rotation of the structure in A, which shows a view from the extracellular side of the 
receptor. (C) Crystal structure of CXCR4 (grey) bound to CVX15 (stick representation). 
The side-chain modeling determined 100 potential orientations of BzF at each site 
examined in the crosslinking experiments, and are highlighted on the structure in stick 
form. The colored density maps indicate the location of the BzF carbonyl for all potential 
orientations of BzF at each position. Position 309 is not shown because this view is from 
the extracellular side of the receptor. (D) A graph of the radial distribution function 
versus the distance. Distance measurements were made from the carbonyl in BzF to the 
closest atom in the CVX15 peptide. The graph for position 309 is not visible on this plot 
because the distance to the ligand is greater than 20 Å. This graph shows that for position 
189, CVX15 has the highest probability of being within the reactive radius of 3.1 Å from 
the carbonyl group in BzF 42. This supports the data that position 189 is the most likely 
site to form a crosslink out of the positions examined. From this model, the predicted 
crosslink site on the ligand is Arg 11, which is conserved in both CVX15 and T140. Note 
this crosslink is independent of the methionine “magnet” effect 116. Adapted with 
permission from (Grunbeck, A., et al. (2011) Biochemistry 50, 3411-3413). Copyright 
(2011) American Chemical Society. 
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Comparison of the photocrosslinking results to the crystal structure of CXCR4 
bound to the homologous T140 peptide ligand, CVX15, has validated our results and 
enabled us to estimate the distance dependency of the photocrosslinking reaction. The 
CXCR4-CVX15 crystal structure shows that Phe 189 is within extracellular loop 2 of 
CXCR4, which borders the main ligand-binding pocket of CXCR4, and lies within close 
proximity of the bound CVX15 ligand. The main ligand-binding pocket for family A 
GPCRs is defined as the pocket between the extracellular segments of transmembrane 
helices III, V, and VI 117. This suggests that T140 has a similar binding site to CVX15, 
which is what we would expect due to their structural similarity. The CXCR4-CVX15 
crystal structure was also used for the side chain modeling study, which estimated that 
BzF needs to be within 3 Å of its target in order to form a UV-dependent covalent 
crosslink. This result agrees with other reports that the minimum required distance to 
form a crosslink with a benzophenone group is approximately 3 Å 42,118.  Since we 
observed the same crosslinking profile when azF was used as the photoactivable probe 
we estimate that the phenylazide group has the same distance requirements as 
benzophenone in this context. 
Through analysis of the complex structure of CXCR4 and CVX15, we propose 
that the site of the crosslink from the BzF at position 189 in CXCR4 is Arg 11 in T140. 
This residue is conserved in both the CVX15 and T140 peptides and is the residue in the 
peptide sequence that is within 3 Å of the photoreactive carbonyl in BzF at position 189. 
The suggestion that benzophenone is reacting with Arg rather than a Met goes against 
other reports that benzophenone favors reaction with Met. This phenomenon is described 
as the methionine “magnet” effect 116.    
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From this study we concluded that this cell-based photocrosslinking method can 
be used to identify the residues in a GPCR that are within a precise distance from a bound 
ligand. We showed that incorporating either BzF or azF into the receptor results in the 
same crosslinking sites and that fluorescein serves as a very sensitive and specific epitope 
tag. We also demonstrated that the crosslinking results agreed with a crystal structure of a 
similar complex and this enabled us to estimate the distance dependency of the 
photocrosslinking reaction to be approximately 3 Å.  We plan to use this methodology to 
map residues in CXCR4 that line the binding site of other CXCR4-specific ligands, such 
as the native chemokine ligand SDF-1α and the CXCR4-specific pepducin ATI-2341. In 
addition, we have applied this targeted photocrosslinking strategy to identify a ligand 
binding site on another chemokine receptor, CCR5, which will be discussed in the 
following sections. 
 
4.1.2. Investigating the binding site of the agonist pepducin ATI-2341 
 
Pepducins are a novel GPCR ligand with an undefined mechanism of action. One 
hypothesis about the mechanism of action of ATI-2341 is that the pepducin mimics the 
active conformation of the i1 loop of CXCR4. An alternative hypothesis is that the 
pepducin binds to an allosteric site on CXCR4 to initiate the active state, which could 
potentially be mimicking a dimer interface or inhibiting dimerization. One way to 
differentiate between these two hypotheses is through the identification of the location of 
the pepducin-binding site. We were unable to directly apply the targeted 
photocrosslinking strategy to investigate the pepducin binding site because at the time we 
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did not have ATI-2341 labeled with a sensitive detection tag. An anti-rhodamine 
antibody did not recognize the rhodamine-labeled ATI-2341 analogue on a dot blot, as 
shown in Figure 2-6. This peptide was detected using fluorescence, but a significant 
amount of protein was required to detect a specific signal above background 31. As an 
alternative we investigated whether ATI-2341 had an overlapping binding site with T140 
through a competition study using FL-T140-BzF as a probe. The results showed that 
crosslinking of FL-T140-BzF to CXCR4 was completely inhibited by unlabeled T140 
and partially inhibited by AMD3100. This might indicate that AMD3100 and T140 have 
similar binding modes. On the other hand, ATI-2341 and maraviroc, a CCR5-specific 
inhibitor, had no effect on crosslinking of FL-T140-BzF to CXCR4. These results suggest 
that ATI-2341 does not bind in a similar region as T140. In addition, since T140 is 
suggested to bind within the conserved main ligand-binding pocket for Family A GPCRs 
these competition results are also in agreement with other reports that ATI-2341 is a 
CXCR4-allosteric modulator.  
We would like to further investigate the binding mode of ATI-2341 using the 
CXCR4_R5i1 receptor. The cell surface ELISA showed that this chimeric receptor is 
expressed at the plasma membrane and at similar levels as WT CXCR4. We now plan to 
evaluate the ligand binding properties and downstream signaling of this receptor in 
collaboration with Dr. Stephen Hill’s Lab at the University of Nottingham. Chemokine 
binding will be determined by imaging cells expressing CXCR4_R5i1 in the presence of 
a fluorescent SDF-1α analogue as described in the methods section. Previously, we were 
able to show that we can measure specific binding of fluorescent SDF-1α to cells 
expressing CXCR4 labeled with a SNAP-tag (Figure 2-8). For this study a SNAP-tagged 
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version of CXCR4_R5i1 will be constructed to enable co-visualization of receptor 
expression and chemokine binding. The Hill lab will carry out the fluorescence 
microscopy to measure chemokine binding. In addition, they will evaluate CXCR4 
mediated inhibition of forskolin induced cAMP production in HEK Glosensor cells stably 
expressing CXCR4_R5i1. This Glosensor cell line from Promega stably expresses a 
luciferase construct containing a cAMP-binding domain. The increase in cAMP 
production leads to an increase in luciferase activity. From these two experiments we can 
then infer whether the i1 loop of CXCR4 is necessary for receptor activation. We can 
then use this information to formulate a new hypothesis about the mechanism of action of 
pepducins.  
 
4.2. Maraviroc Binding Site on CCR5.  
Adapted with permission from (Grunbeck, A., et al. (2012) ACS Chem. Biol. 7, 967-972). 
Copyright (2012) American Chemical Society. 
 
CCR5 is an attractable target for anti-HIV therapeutics because the absence of 
CCR5 at the cell surface, which is seen with the genetic Δ32 variant of CCR5, has little to 
no impact on immune function. In addition, cells expressing this variant are protected 
against HIV-1 infection. These findings directed the development of small molecule HIV 
therapeutics to target CCR5. Maraviroc is one of the small molecule HIV-1 entry 
inhibitors, which targets CCR5, that was identified from a small molecule screen at 
Pfizer. Out of the molecules identified from this screen, maraviroc showed the highest 
CCR5 specificity and most potent pharmacological activity 19. Maraviroc is suggested to 
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be an allosteric modulator of CCR5 and has shown to have inverse agonist activity, 
which indicates that when maraviroc is bound to CCR5 the functional activity of CCR5 is 
decreased to below basal levels 119. Maraviroc is the first GPCR-specific HIV-1 entry 
inhibitor to be approved by the FDA for therapeutic use, but its precise receptor-drug 
binding site interactions have not been defined and the mechanism for how the drug 
blocks HIV-1 entry remains controversial. The clinical relevance of co-receptor blocker 
agents and the increasing frequency of maraviroc resistant viruses also signify the 
importance of investigating the binding interactions between CCR5 and maraviroc120.  
Understanding the precise binding orientation of maraviroc could contribute to the design 
of additional HIV-1 co-receptor blockers.  In addition, recent advances in structural 
studies have confirmed that the arrangement and disposition of the 7-helix bundle of 
family A GPCRs is conserved.  Since maraviroc is hypothesized to bind within a pocket 
in the 7-transmembrane helical domain of CCR5, determining the allosteric binding site 
for maraviroc could facilitate the design of other GPCR allosteric regulators.  
Currently, there is no high-resolution structure of CCR5 and despite significant 
effort, including extensive receptor mutagenesis and medicinal chemistry that has created 
hundreds of small molecule CCR5 ligands, the precise binding site of maraviroc is not 
known experimentally. We have applied the targeted photocrosslinking technique to 
identify the amino acid residues in CCR5 that are within close proximity to the bound 
maraviroc.  
We adapted the targeted photocrosslinking method that was previously described 
for the identification of residues in CXCR4 that were within about 3 Å of FL-T140. The 
obvious limitation of this earlier work was that in essence we mapped the binding site of 
 
96 
  	  
a fluorescein-labeled analogue of T140, and not T140 itself.  In the current work, we 
aimed to devise a strategy to study maraviroc binding without altering the structure of 
maraviroc.  We therefore optimized the targeted photocrosslinking technology in a small-
scale cell-based system so that radioactivity could be used to detect the presence of 
maraviroc.  This allowed us to use a tritiated version of maraviroc, which retained its 
native chemical structure and its pharmacological properties. 
The elevated levels of tritium that are detected in the 25-50 kDa gel fractions are a 
result of a direct UV-dependent crosslink between the UAA incorporated into CCR5 and 
[3H]-maraviroc. Significantly higher tritium counts were detected in this molecular 
weight segment when azF was introduced at position Ile 28 and Trp 86 and when BzF 
was introduced at position Phe 109. The crosslinking patterns observed with BzF and azF 
may differ as a result of either the structural orientation or reactivity of their unique side 
chains. The photoreactive group in benzophenone is a carbon radical, which reacts 
preferentially with C-H bonds. On the other hand the reactive group in phenylazides upon 
photoactivation is a phenylnitrene, which react more non-specifically with the target 
molecule. The differences in the reactivities of these photoreactive molecules could result 
in different preferences for reaction with maraviroc in addition to altering the occurrence 
of intramolecular crosslinks.  Alternatively, the structural difference between the azido 
and benzoyl functional groups might also have had differing effects on ligand affinity for 
the mutant CCR5. 
We performed ligand-binding experiments with [3H]-maraviroc to determine if 
introducing a UAA at any of the positions we tested altered maraviroc binding. In 
addition, three CCR5 BzF mutants were examined in calcium flux assays and found to 
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retain RANTES binding similar to WT. The only CCR5 mutant that was found to have 
substantially reduced maraviroc binding was when residue Trp 86 was replaced with 
BzF. This result suggests that CCR5 W86BzF may have failed to crosslink to maraviroc 
because of decreased ligand binding affinity.  On the other hand, we also detected 
different crosslinking results at position 109 for the two crosslinkers. The binding data 
suggest that maraviroc is able to bind to both the CCR5 F109BzF and CCR5 F109azF 
mutants.  Therefore, we can conclude that the difference in crosslinking between the two 
photoactivable groups at position 109 was a result of a difference in reactivity of the 
photoactivatable crosslinking groups. Other relevant factors that might affect the 
reactivity of these crosslinking groups include the chemical bonds of maraviroc near to 
the reactive moiety and the specific spatial orientation of the side chain.  
We then applied our crosslinking results to evaluate a newly predicted structure of 
the CCR5-maraviroc complex, which was created by our collaborators in Dr. Goddard’s 
Lab at Caltech. They generated a CCR5-maraviroc complex model using the 
GEnSeMBLE structure prediction methodology, which is a Monte Carlo based method 
aimed at sampling all reasonable packings of the 7-helix bundle (they examined 10 
trillion) and selecting an ensemble of 100 low-energy packings likely to play a role in 
binding of various ligands and in the activation process121. The lowest 20 of these 
structures were used to predict the most stable CCR5-maraviroc complex, which was 
used to understand the experimental observations. Dr. Huber calculated 100 different 
conformations of the BzF and azF side chains at each of the eight positions in CCR5 that 
were tested in the crosslinking studies, as was done in the CXCR4-T140 study. Distance 
measurements were then made from either the carbonyl in BzF, or the nitrogen adjacent 
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to the phenyl ring in azF, to the nearest possible non-hydrogen atom in maraviroc. He 
then calculated a probability distribution for the side chain at each of the indicated 
positions to come within 3 Å of contacting a non-hydrogen atom in maraviroc (Figure 4-
2). According to the predicted structures, the only positions in CCR5 with a reasonable 









Figure 4-2. Interpretation of crosslinking data according to a molecular model of the 
CCR5-maraviroc complex. The crosslinking experiments identified three positions in the 
receptor that were able to crosslink to maraviroc when replaced by either azF or BzF. 
These results suggest that these three positions in CCR5 are within about 3 Å from the 
bound maraviroc.  We modeled 100 different conformations of the azF and BzF side 
chains at each of the positions tested in the crosslinking experiments in the context of this 
CCR5-maraviroc model. We then measured the distance from the reactive group in the 
photocrosslinker, which is the carbonyl in BzF or the nitrogen adjacent to the phenyl ring 
in azF, to the nearest non-hydrogen atom in maraviroc. The top panel in this figure 
displays the CCR5-maraviroc model with the side chain predictions at each of the 
positions in CCR5 that were replaced with a UAA. The colored densities represent the 
location of the reactive group in azF (left) and BzF (right) and the colors coordinate with 
the colored boxes under the residue names listed below the bar graph. The bar graph 
shows the probability of the side chains at the indicated position to be within 3 Å of 
contacting a non-hydrogen atom in maraviroc.  In this model only Trp 86, Tyr 108, and 
Phe 109 are found to be within 3 Å of the bound maraviroc.  Experimentally, crosslinking 
was also found between CCR5 I28BzF and maraviroc. Adapted with permission from 




  	  
 
The experimental crosslinking data are consistent with the predictions based on 
the Trp 86 and Phe 109 positions in the CCR5-maraviroc complex.  On the other hand, 
the predicted model suggested that Tyr 108 would be within crosslinking distance of 
bound maraviroc, but no experimental crosslink was observed under the conditions 
tested.  This discrepancy between predictions based on the complex model and the 
experimental data could mean that the complex model is not entirely correct (although 
the other sites were accurately predicted). One possible explanation is that the CCR5 
receptor might adopt a different low-energy conformation for Y108BzF and Y108azF 
mutants. This is plausible because the Goddard lab has found that the Y108A mutant 
does adopt different transmembrane bundle packing when bound to maraviroc. If the 
CCR5-maraviroc complex for the UAA-containing protein does not change, a second 
possibility for the discrepancy could be that the photocrosslinkers at position 108 were 
not able to react due to either a suboptimal orientation of the side chain or the lack of an 
appropriate target bond in maraviroc. Both of these possible explanations are plausible 
because Tyr 108 side chain lies in a tight region near maraviroc, whereas both Trp 86 and 
Phe 109 reside in a more open region.  Thus, to accommodate the BzF and azF UAAs at 
the Tyr 108 position, maraviroc may have to move to a different (but may be proximal to 
original) binding site not accessible to the photocrosslinkers. The computational methods 
can be used to test these suggestions, but we have not yet done so. In addition, position 
28, which formed crosslinks in both the CCR5 I28azF and CCR5 I28BzF mutants, was 
not identified in the model to be within crosslinking distance of maraviroc. This result 
again could indicate limitations of the model.  However, given the location of Ile 28 in 
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the N-terminal tail of CCR5, we favor the possibility that the experimental crosslink 
could suggest an additional maraviroc-binding site, which has also been predicted before 
by others and us104,111. The location of Ile 28, is consistent with a maraviroc “docking 
site” on the extracellular surface of CCR5 and might be relevant for understanding its 
mechanism of action with respect to its function as an HIV-1 entry blocker. To further 
evaluate the exact orientation of maraviroc in the CCR5 ligand-binding pocket, we would 
like to identify the locations of the crosslinks on the maraviroc molecule.  
We plan to use mass spectrometry to identify the site of the crosslink on 
maraviroc. We have optimized a two-step digestion method of CCR5 for mass 
spectrometry analysis. This protocol has led to detection of approximately 50% of 
CCR5’s sequence. Out of the peptides that were identified only one contains a site in 
CCR5 that was identified to crosslink to maraviroc. The sequence of this peptide is 
TGLYFIGFF, where the central Phe is Phe 109. We would now like to apply this 
digestion method to a protein sample containing a crosslinked complex of CCR5 
F109BzF and maraviroc. Additionally, we plan to digest and analyze crosslinked samples 
of CCR5 with FL-MVC-bp and CCR5 F109BzF with FL-maraviroc. These complexes 
have been shown to result in covalent complexes upon UV-light exposure. We have also 
shown that the fluorescein moiety can be used as a purification tag. Therefore an 
advantage of using these crosslinked complexes for mass spectrometry analysis is that 
after digestion of the protein samples the peptide fragment that is crosslinked to the FL-
ligand can be purified. This has the potential to clean up the mass spectra and improve 
identification of the crosslinked site. 
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Another possibility is to perform the crosslinking experiment with a maraviroc 
sample where 50% of the ligand is deuterated. This would aid in the identification of the 
mass peak that corresponds to the peptide crosslinked to maraviroc because there would 
be two mass peaks present that are separated by the mass difference between maraviroc 
and deuterated maraviroc. We have obtained a deuterated version of maraviroc from 
ALSACHIM, where the hydrogens on the two methyl groups have been replaced with 
deuterium. One potential pitfall in the use of a deuterated ligand is if the position of the 
deuterium is at the location required for the hydrogen abstraction step of the crosslinking 
reaction. This could result in a decrease in crosslinking efficiency with the deuterated 
ligand due to the increased bond strength of a carbon-deuterium bond as compared to a 
carbon-hydrogen bond.   
 To our knowledge, this is the first demonstration of a direct chemical crosslink 
between a GPCR and its native small-molecule ligand.  We show that the targeted 
photocrosslinking technology using UAA mutagenesis can be applied to identify the 
binding-site of a small molecule ligand and that tritium is a sensitive detection tag for 
small-scale cell-based assays.  We used the crosslinking results to evaluate a model of the 
CCR5-maraviroc complex and we confirmed that maraviroc binds within the 
transmembrane helix bundle.  This method should prove to be valuable for obtaining 
structural information about the binding site of GPCR allosteric modulators.  In principle, 
the method should be applicable to any receptor-ligand complex where the receptor can 
be heterologously expressed in mammalian cells in culture and isotopically-labeled 




  	  
 
CHAPTER 5: Conclusions and Future Perspectives 
 
5.1. Targeted Photocrosslinking Strategy 
 
We have established a live-cell targeted photocrosslinking technique for the 
identification of residues in a GPCR that are within a precise distance from a ligand-
binding pocket. The targeted photocrosslinking strategy is unique compared to 
prototypical photoaffinity ligand studies, as the location of the crosslinker in the receptor 
is known prior to ligand binding and UV illumination. We have described the 
introduction of two UAAs containing distinct photoactivatable groups, BzF and azF, into 
the HIV-1 co-receptors, CCR5 and CXCR4. Each of the receptor UAA mutants were 
examined for UV-specific crosslinking to either a fluorescein labeled peptide ligand or a 
tritiated small molecule ligand. In these studies we demonstrated the necessity of a 
chromatography step under denaturing conditions and a sensitive detection tag on both 
the receptor and ligand for identification of a UV-induced covalent complex. The 
application of the photocrosslinking strategy to the CXCR4-T140 complex enabled us to 
validate our results with a crystal structure and estimate the distance dependency of the 
photocrosslinking reaction mechanism. In the CCR5-maraviroc study we identified 
different crosslinking profiles with the two UAAs, which demonstrated the utility of 
applying two photoactivatable probes with a different size and reactivity. We also 
exhibited the bigger picture applications of photocrosslinking studies by evaluating a 
molecular model of the complex with the crosslinking data. 
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In the future, we would like to expand the targeted photocrosslinking technique in 
several ways. The first is to further analyze a crosslinked GPCR UAA-ligand complex 
using mass spectrometry and identify the location of the crosslink on the ligand. 
Additionally, we would like to apply the targeted photocrosslinking strategy to identify 
the binding interactions between GPCRs and their other binding partners. Advancing the 
photocrosslinking technique in these ways will bring this chemically-precise strategy to 
its full potential of creating a structural model of a GPCR signaling complex in its native 
environment. 
 
5.1.1. MS analysis to identify site of crosslink in ligand  
 
Mass spectrometry analysis is the obvious choice for a high sensitivity technique 
to detect the location of the crosslink in the ligand. As a proof-of-principle experiment, 
we would like to identify the location of the crosslink on maraviroc in the CCR5 
F109BzF-maraviroc crosslinked complex. We have optimized a two-step digestion 
method of CCR5, which involves CNBr treatment followed by trypsin digestion, to detect 
a peptide fragment in the receptor that contains Phe 109. We plan to perform this 
experiment using either FL-maraviroc or deuterated maraviroc, as described in the 
discussion section. In theory, we could also analyze the CCR5 I28azF-maraviroc 
complex with mass spectrometry as well to prove or disprove our hypothesis of a second 
maraviroc-binding site, although the digestion steps would need to be altered to allow for 
detection of the receptor fragment containing Ile 28. Analysis of the mass spectrometry 
results could be complicated as the fragmentation profile of maraviroc is unknown, but if 
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the site of attachment in the maraviroc molecule is identified we can infer the orientation 
of maraviroc in the binding site. 
 
5.1.2. Detecting crosslinks to other GPCR binding partners 
 
Both T140 and maraviroc are extracellular GPCR ligands with inhibitory 
properties. These two ligands facilitate formation of receptor-ligand complexes at the 
plasma membrane because the ligand can be added at saturating concentrations and 
neither T140 nor maraviroc are reported to induce receptor internalization. Stabilizing 
GPCR complexes prior to UV illumination is optimal for increasing the yield of 
crosslinked complexed, which improves signal-to-noise in the detection step. Other 
examples of CCR5- and CXCR4-binding molecules that can be added to cells at specific 
concentrations and are interesting to study with targeted photocrosslinking are native 
chemokine ligands, HIV-1 envelope proteins, and pepducins. We have tested antibodies 
to SDF-1α and the HIV-1 envelope protein gp120 and shown that these antibodies 
recognize the protein on a denaturing gel (Figure 2-7 A&C). Each of these antibodies 
reacted with epitopes in the native sequence of the protein. Detection could also be 
improved by introducing an engineered antibody epitope, such as a FLAG or HA tag. For 
the pepducin, we have an analogue with a rhodamine label, which was detected on a 
SDS-PAGE gel with fluorescence, but the anti-rhodamine antibodies we tested did not 
recognize this label. Therefore a pepducin analogue containing a fluorescein-label or 
radiolabel will need to be synthesized for targeted photocrosslinking studies.  
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GPCRs are transmembrane proteins and another component of their signaling 
complexes are the cytoplasmic binding partners, such as G proteins and β-arrestin. 
Investigating the binding interactions with cytoplasmic proteins in a live cell complex is a 
bit more involved because these proteins need to be co-expressed rather than added 
extracellularly. We have tested several G protein antibodies that recognize either the α or 
β subunit of G proteins expressed endogenously in HEK293T cells (Figure 2-7B). To 
improve detection of the G protein subunits with an engineered antibody epitope, the G 
protein will need to be heterologously expressed in addition to the GPCR UAA mutants. 
Identifying the binding interactions between a receptor and G protein could facilitate our 
understanding of ligand functional selectivity and G protein subtype specificity.  
 
5.2. Insights into the Structure and Function of GPCR-ligand Complexes.  
Adapted from (Grunbeck, A. and Sakmar, T.P. “Probing GPCR-Ligand Interactions with 
Targeted Photoactivatable Crosslinkers,” in preparation.) 
 
 Over the past five years there has been a significant increase in the number of 
solved GPCR crystal structures and the rate of newly available structures is increasing 
dramatically as enabling technologies have become disseminated. These structures 
provide atomic-level information about one static structure of a receptor, usually in 
complex with a ligand or drug. The conditions required for standard crystallography 
techniques are not always amenable for the analysis of every receptor-ligand complex.  
Photoactivatable crosslinking studies are one alternative approach to gain structural 
information about these complexes. The distance dependency of these photolytic 
 
107 
  	  
reactions allows for the precise mapping of biological interactions. In fact, targeted 
photocrosslinking and crystallography are complementary methods because the 
systematic interpretation of crosslinking data requires knowledge of structure.  The 
availability of a single structure of a GPCR in complex with a ligand can facilitate cell-
based photocrosslinking studies with large numbers of ligands or ligand analogues.  The 
only limiting factor is the problem of detecting a crosslink in cases where appropriately 
labeled ligands are not readily available.   
Since the origins of photocrosslinking fifty years ago, many studies have been 
performed to investigate the interactions between GPCRs and their ligands. However, the 
recent coincident advances in the structural biology of GPCRs and unnatural amino acid 
mutagenesis of GPCRs has led to a resurgence of interest in targeted photocrosslinking to 
probe receptor ligand-binding sites.  By interpreting targeted crosslinking data in light of 
available crystal structures more accurate models of receptor-ligand complexes can be 
created. The complementarity of these two structural techniques has the potential to 
advance our understanding of the structure and function of GPCR-ligand interactions.  
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